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Abstract
Summary This report describes the epidemiology, burden,
and treatment of osteoporosis in the 27 countries of the
European Union (EU27).
Introduction Osteoporosis is characterized by reduced bone
mass and disruption of bone architecture, resulting in in-
creased risk of fragility fractures which represent the main
clinical consequence of the disease. Fragility fractures are
associated with substantial pain and suffering, disability and
even death for affected patients and substantial costs to
society. The aim of this report was to characterize the burden
of osteoporosis in the EU27 in 2010 and beyond.
Methods The literature on fracture incidence and costs of
fractures in the EU27 was reviewed and incorporated into a
model estimating the clinical and economic burden of oste-
oporotic fractures in 2010.
Results Twenty-two million women and 5.5 million men
were estimated to have osteoporosis; and 3.5 million new
fragility fractures were sustained, comprising 610,000 hip
fractures, 520,000 vertebral fractures, 560,000 forearm frac-
tures and 1,800,000 other fractures (i.e. fractures of the
pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum
and other femoral fractures). The economic burden of inci-
dent and prior fragility fractures was estimated at € 37
billion. Incident fractures represented 66 % of this cost,
long-term fracture care 29 % and pharmacological preven-
tion 5 %. Previous and incident fractures also accounted for
1,180,000 quality-adjusted life years lost during 2010. The
costs are expected to increase by 25 % in 2025. The majority
of individuals who have sustained an osteoporosis-related
fracture or who are at high risk of fracture are untreated and
the number of patients on treatment is declining.
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Conclusions In spite of the high social and economic cost of
osteoporosis, a substantial treatment gap and projected in-
crease of the economic burden driven by the aging
populations, the use of pharmacological interventions to
prevent fractures has decreased in recent years, suggesting
that a change in healthcare policy is warranted.
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Foreword
Osteoporosis, literally “porous bone”, is a disease characterized
by weak bone. It is a major public health problem, affecting
hundreds of millions of people worldwide, predominantly post-
menopausal women. The main clinical consequence of the
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disease is bone fractures. It is estimated that one in three women
and one in five men over the age of 50 worldwide will sustain
an osteoporotic fracture. Hip and spine fractures are the two
most serious fracture types, associated with substantial pain and
suffering, disability, and even death. As a result, osteoporosis
imposes a significant burden on both the individual and society.
During the past two decades, a range of medications has be-
come available for the treatment and prevention of osteoporo-
sis. The primary aim of pharmacological therapy is to reduce
the risk of osteoporotic fractures.
The objective of this report is to review and describe the
current burden of osteoporosis and highlight recent advances
and ongoing challenges for treatment and prevention of the
disease. The report encompasses both epidemiological and
health economic aspects of osteoporosis and osteoporotic frac-
tures with a geographic focus on EU27. Projections of the future
prevalence of osteoporosis and fracture incidence, the direct and
total societal burden of the disease, and the consequences of
different intervention strategies receive special attention. The
report may serve as a basis for the formulation of healthcare
policy concerning osteoporosis in general and the treatment and
prevention of osteoporosis in particular. It may also provide
guidance regarding the overall healthcare priority of the disease.
The report is divided into five chapters:
1. Introduction to osteoporosis
This introductory chapter briefly reviews the way in
which osteoporosis and the associated fractures are
defined, describes the most common osteoporotic frac-
tures, and the extent of the burden worldwide.
2. Medical innovation and its clinical uptake in the
management of osteoporosis The second chapter reviews
the measurement of bone mineral density, diagnosis of
osteoporosis, methods for assessment of fracture risk, the
development of interventions that reduce the risk of frac-
tures, practice guidelines, and the cost-effectiveness of
osteoporosis treatments.
3. Epidemiology of osteoporosis
The third chapter reviews the epidemiology and con-
sequences of osteoporosis and fractures, as well as
different approaches for setting intervention thresholds
(i.e. at what fracture risk it is appropriate to initiate
treatment).
4. Burden of fractures
The fourth chapter presents a model estimation of the
burden of osteoporosis in the EU27 for 2010. The burden
is described in terms of fractures, costs, and QALYs lost.
Fracture burden is also projected to the year 2025 based
on expected demographic changes.
5. Uptake of osteoporosis treatments
The fifth chapter provides a description of the current
uptake of osteoporosis treatments, that is, how many pa-
tients of those eligible for treatment that actually can be
treated in the EU27. International sales data from 2001 and
forward were used to analyse international variations in
treatment uptake.
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1. Introduction to osteoporosis
Summary
This introductory chapter briefly reviews the way in which
osteoporosis and the associated fractures are defined,
describes the most common osteoporotic fractures, and
the extent of the burden worldwide.
The key messages of this chapter are:
Osteoporosis is characterized by reduced bone mass and
disruption of bone microarchitecture, resulting in increased
bone fragility and increased fracture risk.
In 1994 and 2008, the WHO published diagnostic criteria for
osteoporosis in postmenopausal women based on the T-score for
bone mineral density (BMD). Osteoporosis is defined as a value
for BMD 2.5 standard deviations (SD) or more below the young
female adult mean (T-score less than or equal to −2.5 SD).
Based on these diagnostic criteria, approximately 6 % of men
and 21 % of women aged 50–84 years have osteoporosis
affecting 27.6 million men and women in the EU in 2010.
The most common osteoporotic fractures are those at the
hip, spine, forearm and humerus. At the age of 50 years, the
remaining lifetime probability of one of these fractures is
22 % and 46 % in men and women, respectively.
There are very large variations in the incidence of osteoporotic
fractures between and within countries for reasons that are not
known, but are partly associated with economic prosperity.
Osteoporosis causes more than 8.9 million fractures annu-
ally worldwide and over one-third of all osteoporotic frac-
tures occur in Europe.
In Europe osteoporotic fractures account for 2 million dis-
ability adjusted life years (DALYs) annually, somewhat mo-
re than are accounted for by hypertensive heart disease or
rheumatoid arthritis.
The number of osteoporotic fractures is rising in many coun-
tries. Reasons for this relate in part to the increased longevity of
the population. The age- and sex-specific incidence of fracture
has also increased in some but not all countries.
1.1 Introduction and aims of the report
Osteoporosis is characterized by reduced bone mass and dis-
ruption of bone architecture, resulting in increased bone fra-
gility and increased fracture risk [1]. The publication of a
World Health Organization (WHO) report on the assessment
of fracture risk and its application to screening for
postmenopausal osteoporosis in 1994 provided diagnostic
criteria for osteoporosis based on the measurement of bone
mineral density (BMD) and recognized osteoporosis as an
established and well-defined disease that affected more than
75 million people in the United States, Europe and Japan [2].
Osteoporosis represents a major non-communicable disease
of today and is set to increase markedly in the future. There is
underutilisation of the measures available to combat the disease
and there is therefore a need for assessment of best practices in
prevention and treatment, since the adoption of these across
countries can potentially result in significant reductions in the
burden of this disease. This report reviews country-specific
information on the application of new technologies in osteopo-
rosis, the epidemiology of fracture, future trends, and the uptake
of treatments. The aim is to quantify the burden of osteoporosis
in terms of prevalence, fractures, patients at risk, uptake of
treatment, mortality and the societal costs in different countries
using a commonmethodology. The countries reviewed comprise
member states of the EU. An earlier report reviewed the larger
populations of Europe (Spain, Italy, France, Germany and the
UK) and Sweden [3]. The present review extends this outreach.
The consequences of osteoporosis reside in the fractures
that arise. This introduction covers briefly the way in which
osteoporosis is defined, describes the most common osteo-
porotic fractures, and the extent of the burden worldwide
shown in current literature. Parts of the introduction have
been taken from the earlier report [3] that considered the
burden of osteoporosis in the five major EU countries and
Sweden where relevant to the context of the present report.
1.2 Measurement of BMD
The description of osteoporosis captures the notion that low
bone mass is an important component of the risk of fracture,
but other abnormalities such as micro-architectural deterio-
ration contribute to skeletal fragility. Ideally, clinical assess-
ment of the skeleton should capture all these determinants of
fracture risk, but at present the assessment of bone mass is
the only aspect that can be readily measured in clinical
practice, and forms the cornerstone for the general manage-
ment of osteoporosis being used for diagnosis, risk predic-
tion, and monitoring of patients on treatment [2, 4, 5].
BMD is the amount of bone mass per unit volume (volumet-
ric density, g/cm3), or per unit area (areal density, g/cm2), and
both can be measured in vivo by densitometric techniques. For
the purpose of this report BMD refers to an areal BMD unless
otherwise specified. A large variety of techniques is available [2]
but the most widely used techniques by far are based on x-ray
absorptiometry in bone, particularly dual energy x-ray absorpti-
ometry (DXA). DXA is based on the absorption of x-rays which
is very sensitive to the calcium content of tissue, of which bone
is themost important fraction. DXAprovides a two-dimensional
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areal value rather than a volumetric density and thus is
influenced by bone size as well as true density. The most
commonly measured sites are the lumbar spine (L1-L4) and
the proximal femur. However, in older people the accuracy of
measurements in the lumbar spine may be impaired by scoli-
osis, vertebral deformity, osteophytes and extraskeletal calci-
fication and the proximal femur is the reference site for
diagnosis [5, 6]. Lumbar spine measurements are most widely
used tomonitor treatment since they are sensitive to treatment-
induced changes. DXA techniques using the lateral view of
the spine rather than in the customary postero-anterior projec-
tion are increasingly used to detect vertebral fractures [7, 8].
1.3 Defining osteoporosis
The diagnostic criterion for osteoporosis is based on the measure-
ment of BMD [9]. BMD ismost often described as a T-score or Z-
score, both of which are units of SD. The Z-score describes the
number of SDs by which the BMD in an individual differs from
the mean value expected for age and sex (Fig. 1). The T-score
describes the number of SDs by which the BMD in an individual
differs from themean value expected in young healthy individuals.
The operational definition of osteoporosis is based on the
T-score for BMD in women [2, 9] and is defined as a value
for BMD 2.5 SD or more below the young female adult mean
(T-score less than or equal to –2.5 SD) as shown in Figure 2.
This threshold was originally developed for measurements
of BMD at the spine, hip, or forearm. More recently, the
operational definition of osteoporosis has been refined by
WHO with the femoral neck as the standard measurement
site and the use of an international reference standard for the
calculation of the T-score [6]. The reference population for
both men and women is the mean and SD values in young
women from the NHANES III study [10]. Thus the diagnos-
tic criterion for men uses the same threshold for BMD as that
for women. This arises fortuitously because for any age and
BMD at the femoral neck, the risk of hip fracture or a major
osteoporotic fracture is approximately the same in men and
women [11–13]. Note that the use of the T-score threshold is
inappropriate in children or adolescents.
For the purposes of this report, the term osteoporosis
refers to the densitometric criterion outlined above. These
considerations should not be taken, however, to infer that
the use of other techniques or other sites do not have clinical
utility for the management of patients where they have been
shown to provide information on fracture risk. It is also
relevant to make the distinction between the definition of
osteoporosis based on BMD and a clinical diagnosis based
on the occurrence of fragility fractures. Finally, it is impor-
tant to recognise that the presence or absence of osteoporo-
sis based on BMD is not synonymous with an intervention
threshold which is more appropriately based on fracture risk
rather than on BMD alone.
1.4 Prevalence of osteoporosis
Because the distribution of BMD in the young healthy
population is normally distributed [14] and bone loss
occurs with advancing age, the prevalence of osteoporosis
increases with age. The prevalence of osteoporosis in
Fig. 1 Schematic diagram showing the mean BMD with SD intervals
in women by age and the derivation of Z-scores and T-scores from
BMD
Fig. 2 The distribution of BMD in young healthy women in SD units
and threshold values for osteoporosis and low bone mass
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Sweden using the WHO criterion is shown for Swedish
men and women in Table 1 [15]. Approximately 6 % of
men and 21 % of women aged 50–84 years are classified
as having osteoporosis. The prevalence of osteoporosis in
women over the age of 50 years is 3–4 times greater than
in men—comparable to the difference in lifetime risk of an
osteoporotic fracture in men and women.
For the purposes of this report, it is assumed that the
mean femoral neck BMD is similar across countries at the
age of 50 years and so too is the rate of bone loss at the
femoral neck with age. The same assumptions have been
used elsewhere [3, 16, 17]. The assumptions are consistent
with empirical observation in some [5, 18–20] but not all
studies [21–24]. Although differences in the age-dependent
BMD (and hence the prevalence of osteoporosis) have been
reported between countries, the differences are relatively
small [5, 22, 24] and most studies are on limited sample
sizes, subject to selection bias, undertaken on a regional
rather than national basis and cross-sectional in nature. It
is notable that the variations in BMD between populations
are substantially less than variations in fracture risk. Indeed,
age- and sex-specific risks of hip fracture differ more than
10-fold, even within Europe [25–28]. These differences are
very much larger than can be accounted for by any differ-
ences in BMD between communities.
With these caveats, the prevalence of densitometric
osteoporosis varies somewhat between member states
according to the demography of the population. In men
over the age of 50 years the prevalence of osteoporosis
varies from 5.9 % (Poland) to 7.2 % (Luxembourg). In
women, the rates vary from 19.1 % (Cyprus) to 23.5 %
(France). Further details on a country by country basis are
given in Chapter 3 and the country-specific reports pub-
lished as a compendium in this issue of Archives in
Osteoporosis. The prevalence of osteoporosis in the EU
is estimated at 27.6 million in 2010 (Fig. 3). The extension
of this report from the 5 major countries (EU5) to the
EU27 increases the proportion of men and women with
osteoporosis by 35 %.
Table 1 Prevalence of osteoporosis at the age intervals shown in Sweden using female-derived reference ranges at the femoral neck [15]
Fig. 3 The prevalence distribution of osteoporosis in the EU and the 5
countries with the highest populations in 2010
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1.5 Defining osteoporotic fracture
Osteoporosis is manifested by fractures but the defini-
tion of an osteoporotic fracture is not straightforward.
Opinions differ concerning the inclusion or exclusion of
different sites of fracture in describing osteoporotic frac-
tures. One approach is to consider all fractures from
low energy trauma as being osteoporotic. “Low energy”
may variously be defined as a fall from a standing
height or less, or trauma that in a healthy individual
would not give rise to fracture [29]. This characteriza-
tion of low trauma indicates that the vast majority of
hip and forearm fractures are low energy injuries or
fragility fractures [30, 31]. The consideration of low
energy has the merit of recognizing the multifactorial
causation of fracture, but osteoporotic individuals are
more likely to fracture than their normal counterparts
following high energy injuries [31]. As might be
expected, there is also an imperfect concordance be-
tween low energy fractures and those associated with
reductions in BMD [32, 33].
The rising incidence of fractures with age does not
provide direct evidence for osteoporosis, since a rising
incidence of falls could also be a cause. By contrast, a
lack of increasing incidence with age is reasonable
presumptive evidence that a fracture type is unlikely
to be osteoporosis-related. An indirect arbiter of an
osteoporotic fracture is the finding of a strong associa-
tion between the fracture and the risk of classical
osteoporotic fractures at other sites. Vertebral fractures,
for example, are a very strong risk factor for subse-
quent hip and vertebral fracture [34–38], whereas fore-
arm fractures predict future vertebral and hip fractures
[39].
Due to the difficulties of knowing which fractures
have been caused by low energy trauma, the approach
used in this report and elsewhere is to characterize frac-
ture sites as osteoporotic when they are associated with
low bone mass and their incidence rises with age after
the age of 50 years [40]. The most common fractures
defined in this way are those at the hip, spine and
forearm, and humerus but many other fractures after the
age of 50 years are related at least in part to low BMD
and should be regarded as osteoporotic [32, 40–42].
These include fractures of the ribs, tibia (in women, but
not including ankle fractures), pelvis and other femoral
fractures (Fig. 4). Their neglect underestimates the bur-
den of osteoporosis, particularly in younger individuals.
Under this schema, the fracture sites that would be
excluded are those at the ankle, hands and feet, digits,
skull and face.
1.6 Common osteoporotic fractures
The most common osteoporotic fractures comprise ver-
tebral fractures, fractures of the forearm (particularly
Colles’ fracture), hip fractures, and proximal humerus
fractures [2]. In Sweden, the remaining lifetime risk at
the age of 50 years of sustaining a hip fracture is
22.9 % in women and 10.7 % in men. The remaining
lifetime risk of a major osteoporotic fracture (clinical
spine, hip, forearm or humeral fracture) is 46.4 % in
women and 22.4 % in men [43] (Table 2). The vast
majority of osteoporotic fractures occur in elderly
women [44]. Overall, women have about twice as high
a risk of sustaining any fracture than men. However,
there are variations between different fracture sites.
For example women have about a 5 times higher risk
of sustaining a forearm fracture than men but less than
twice the risk of sustaining a spine fracture. The
reasons for this relate in part to differences in bone
density at maturity and in particular to the loss of
bone that occurs after the menopause. In addition,
women live longer than men and are exposed, there-
fore, for longer periods to a reduced bone density and
other risk factors for osteoporosis or fracture. Men
have higher rates of fracture-related mortality than
women [45], possibly related to higher rates of co-
morbidity [46, 47].
Fig. 4 Hazard ratio and 95 % confidence intervals for osteoporosis as
judged by BMD at the hip according to fracture site in women from
France [41]
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The incidence of fragility fractures increases markedly with
age, though the rate of rise with age differs for different
fracture outcomes. For this reason, the proportion of frac-
tures at any site also varies with age. This is most evident for
forearm and hip fractures [48] (Fig. 5). Thus forearm frac-
tures account for a greater proportion at younger ages than
in the elderly. Conversely, hip fractures are rare at the age of
50 years but become the predominant osteoporosis fracture
from the age of 75 years. In women, the median age for
distal forearm fractures is around 65 years and for hip
fracture, 80 years. Thus both the number of fractures and
the type of fracture are critically dependent on the age of the
populations at risk.
1.6.1 Hip fracture
Hip fracture is the most serious osteoporotic fracture. Most are
caused by a fall from the standing position, although they
sometimes occur spontaneously [49]. The risk of falling in-
creases with age and is somewhat higher in elderly women
than in elderly men. About one-third of elderly individuals fall
annually, with the result that 5 % will sustain a fracture and
1 % will suffer a hip fracture [50]. Hip fracture is painful and
nearly always necessitates hospitalisation.
A hip fracture is a fracture of the proximal femur, either
through the femoral cervix (sub-capital or trans-cervical:
intra-capsular fracture) or more distally through the trochan-
teric region (intra-trochanteric: extra-capsular fracture). Tro-
chanteric fractures are more characteristically osteoporotic,
and the increase in age-specific and sex-specific risks for hip
fracture is greater for trochanteric than for cervical fractures
[51]. Trochanteric fractures are also more commonly asso-
ciated with a prior fragility fracture.
Displaced cervical fractures have a high incidence of
malunion and osteonecrosis following internal fixation,
and the prognosis is improved with hip replacement. Tro-
chanteric hip fractures appear to heal normally after ade-
quate surgical management. Complications may arise
because of immobility. The outcome is much poorer where
surgery is delayed for more than 2 days. Up to 20 % of
patients die in the first year following hip fracture, mostly as
a result of serious underlying medical conditions [52, 53]
and less than half of survivors regain the level of function
that they had prior to hip fracture [54]. Patients with hip
fracture often have significant co-morbidities, so that not all
deaths associated with hip fracture are due to the hip fracture
event. It is estimated that approximately 30 % of deaths are
Fig. 5 The site specific pattern of osteoporotic fractures between the ages of
50–54 and 85–89 years in women from Sweden [48]
Table 2 Remaining lifetime probability of fracture (%) in men and women from Sweden at the ages shown. The risk ratio refers to the female/male
probabilities [43]
a
Clinical spine fracture
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causally related [55]. When this is taken into account, hip
fracture causes more deaths than road traffic accidents in
Sweden and about the same number as those caused by
breast cancer (Table 3).
Compared with other fractures, a great deal of information is
available on the epidemiology of hip fracture. The reason is
that nearly all patients with hip fracture are admitted to
hospital and appear on discharge records. In most cases
information is also available from surgical records. At most
other sites of fracture, a minority of patients are admitted but
may attend hospital on an outpatient basis.
1.6.2 Vertebral fracture
The vast majority of vertebral fractures are a result of
moderate or minimal trauma [56]. The incidence and mor-
bidity of vertebral fractures are not well documented, in part
related to the difficulties in defining vertebral fracture, and
also because of the non-specific nature of the morbidity
occasioned by the disorder (e.g., back pain). Thus, the
diagnosis is made on a change in the shape of the vertebral
body on x-rays. The deformities that result from osteopo-
rotic fracture are usually classified as a crush fracture (in-
volving compression of the entire vertebral body), a
wedge fracture (in which there is anterior or posterior
height loss), and biconcavity (where there is relative main-
tenance of the anterior and posterior heights with central
compression of the end-plate regions). A number of mor-
phometric approaches has been developed to quantify the
shape of the vertebral body from radiographs of the lateral
spine, and this has helped in defining the prevalence and
incidence of vertebral fracture. A widely used clinical sys-
tem is to classify vertebral fractures as mild (20–25 %
height loss), moderate (25–40 % height loss), or severe
(>40 % height loss) [57].
A further problem in describing the epidemiology of
vertebral fracture is that not all fractures come to clinical
attention [58–61]. Estimates for the proportion of vertebral
deformities that reach primary care attention vary, however,
in different countries [58, 60–62]. In register studies, the
discharge rate for hospitalised vertebral fractures is closely
correlated with the discharge rate for hip fracture [59]. In
Sweden, approximately 23 % of vertebral deformities come
to clinical attention in women, and a somewhat higher
proportion in men [60]. A similar proportion has been
observed in the placebo wing of multinational intervention
studies [63]. For the purpose of this report that deals with
the burden of disease, vertebral fractures are defined as
those coming to clinical attention (‘clinical vertebral
fractures’).
Vertebral fractures may give rise to pain, loss of height and
progressive curvature of the spine (kyphosis). The conse-
quences of kyphosis include difficulties in performing daily
activities and a loss of self-esteem due to the change in body
shape. Severe kyphosis also gives rise to respiratory and
gastrointestinal disorders. Although vertebral fractures that
come to clinical attention are less costly than hip fractures,
the morbidity from an acute fracture in the first year is nearly
as severe as that due to a hip fracture [64] and is associated
with an increase inmortality [65]. Vertebral fractures are also a
very strong risk factor for a further fracture at the spine and
elsewhere [34–36, 66].
1.6.3 Distal forearm fracture
The most common distal forearm fracture is a Colles’ frac-
ture. This fracture lies within 2.5 cm of the wrist joint
Table 3 Causes of death in men and women aged 45 years or more from Sweden [55]
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margin and is associated with dorsal angulation and dis-
placement of the distal fragment of the radius. It may be
accompanied by a fracture of the ulna styloid process. A
Smith fracture resulting in ventral angulation usually fol-
lows a forcible flexion injury to the wrist and is relatively
uncommon in the elderly.
The cause of fracture is usually a fall on the outstretched
hand [54]. Although fractures of the forearm cause less
morbidity than hip fractures, are rarely fatal, and seldom
require hospitalisation, the consequences are often
underestimated. Fractures are painful and need 4–6 weeks
in plaster. Approximately 1 % of patients with a forearm
fracture become dependent as a result of the fracture
[67], but nearly half report only fair or poor functional
outcome at 6 months [68]. There is a high incidence of
algodystrophy—a syndrome which gives rise to pain, ten-
derness, stiffness and swelling of the hand, and more rarely
to frozen shoulder syndrome [69]. Moreover, the risk of
other osteoporotic fractures in later life is also increased
after Colles’ fracture [34, 35, 66].
1.7 Fracture burden worldwide
There is a marked difference in the incidence of hip
fracture worldwide and probably in other osteoporotic
fractures [28] (Fig. 6). Indeed, the difference in inci-
dence between countries is much greater than the
differences in incidence between sexes within a country
[26, 27]. The EU comprises countries with some of the
highest hip fracture rates which are considered in
Chapter 3.
Many risk factors for osteoporosis, and in particular
for hip fracture have been identified which include a
low body mass index (BMI), low calcium intake, re-
duced sunlight exposure and early menopause. These
may have important effects within communities but do
not explain differences in risk between communities.
The factor which best predicts this is socio-economic
prosperity that in turn may be related to low levels of
physical activity [70] (Fig. 7). This is plausible, but
only a hypothesis. It will be important to determine
whether this and other factors are truly responsible for
the heterogeneity of fracture risk. If such factors can be
identified and are reversible, the primordial prevention
of hip fracture in those communities with presently low
rates might be feasible and, conversely, primary preven-
tion of hip fracture in communities with high rates
might be undertaken.
Osteoporosis causes more than 8.9 million fractures
annually worldwide (Table 4)—approximately 1,000 per
hour [48]. Fracture rates are higher in the western
world than in other regions so that, despite the lower
population, slightly more than one-third of all osteopo-
rotic fractures occur in Europe.
Fig. 7 Correlation between age standardized incidence of hip fracture
in women in different countries and gross domestic product (GDP) per
capita [70]
Fig. 6 Annual incidence of hip fracture in men and women from
selected countries standardized to the world population for 2010
[28]. EU countries are highlighted
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The global burden of osteoporosis can be quantified by
DALYs [71]. This integrates the years of life lost due to
a fracture and the disability in those that survive. A year
lost due to premature mortality is equal to one DALY. If
the quality of life is halved by a fracture (1=death; 0=
perfect health), then a year of life disabled is equal to a
DALY of 0.5. In the year 2000 there were an estimated
9 million osteoporotic fractures world-wide of which 1.6
million were at the hip, 1.7 million at the forearm and
1.4 million were clinical vertebral fractures. The total
DALYs lost was 5.8 million accounting for 0.83 % of
the global burden of non-communicable disease. In Eu-
rope osteoporotic fractures account for 2 million DALYs
annually, somewhat more than accounted for by hyper-
tensive heart disease and rheumatoid arthritis [48], but
less than chronic obstructive pulmonary disease (Fig. 8).
With the exception of lung cancer, fractures due to
osteoporosis account for more combined deaths and
morbidity than any cancer type (Fig. 9). Collectively,
osteoporotic fractures account for approximately 1 % of
the DALYs attributable to non-communicable diseases
in Europe.
1.8 The future burden
The frequency of osteoporotic fracture is rising in many
countries. In some other countries such as the UK and
US, rates have stabilised or even slightly decreased
[72, 73]. Reasons for an increase relate in part to the
increased longevity of the population, which is occur-
ring both in the developed and developing world.
Fig. 8 Burden of diseases estimated as DALYs in 2002 in Europe for
the non-communicable diseases shown [48]. IHD: Ischemic heart
disease, COPD: Chronic obstructive pulmonary disease, OA: Osteo-
arthritis, HD: heart disease, RA: Rheumatoid arthritis, BPH: Benign
prostatic hyperplasia
Table 4 Number of osteoporotic fractures by site, in men and women aged 50 years or more in 2000, by WHO region [48]
aIncludes Australia, China, Japan, New Zealand and the Republic of Korea
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Improvements in socio-economic prosperity that in turn
decrease everyday levels of physical activity may be a
factor associated with increasing fracture rates. In Eu-
rope, the total population will not increase markedly
over the next 25 years, but the proportion accounted
for by the elderly will increase by 56 % in men and by
41 % in women. In the developing world, the total
population as well as life expectancy of the elderly will
increase by more than two-fold over the next 25 years,
so that osteoporotic fractures will assume even greater
significance for health care planning. For the very el-
derly, the size of the population aged 85 years or more
will increase by 129 % in men and by 73 % in women.
These projections are relatively robust in the sense that
all individuals who will be elderly in 2035 are already
born.
There are important differences in demographic shifts
between the EU countries. For example, the number of
men and women aged 65 years or more will increase
by 50.6 % in the EU but the increase ranges from
10.4 % in Bulgaria to 117.3 % in Ireland (Fig. 10).
Moreover the economic burden will increase further in
the sense that the productive segment of the population
to sustain this increase will decrease in size. For exam-
ple, in 2010 the population aged 20–64 years was
307.3 million but will decrease by 9 % to 279.8 mil-
lion in 2035 [74].
The number of hip fractures has been estimated to
more than double over an interval of 50 years assuming
no change in age-specific risk [73, 75] but would more
than quadruple with rather conservative estimates of the
secular trend [73] (Table 5).
Fig. 10 Predicted increases in the population (men and women) aged
65 years or more in the EU by country [74]
Fig. 9 Burden of diseases estimated as DALYs for osteoporosis and
specific sites of cancer in 2002 in Europe [48]
Table 5 Number of hip fractures estimated worldwide for the year
2000 and those projected by demographic changes alone and those
assuming additional increases in age- and sex-specific risk [73]
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2. Medical innovation and its clinical uptake
in the management of osteoporosis
Summary
In recent years, there has been a number of advances, partic-
ularly in the measurement of BMD, diagnosis of osteoporosis,
the assessment of fracture risk, the development of interven-
tions that reduce the risk of fractures and the production of
practice guidelines. This chapter describes the current state of
these aspects in the field of osteoporosis. Also, the cost-
effectiveness of osteoporosis treatments is addressed.
The key messages of this chapter are:
BMD forms a cornerstone for the general management of
osteoporosis, being used for diagnosis, fracture risk assess-
ment, selection of patients for treatment and monitoring of
patients on treatment.
There is marked heterogeneity in the availability of DXA in
the EU, and most countries have insufficient resources to
implement practice guidelines.
There is an important distinction to be made between the use
of BMD for diagnosis and for fracture risk assessment. Frac-
ture risk assessment is improved by the concurrent consider-
ation of risk factors that operate independently of BMD.
FRAX models integrate the weight of clinical risk factors
(CRFs) for fracture risk, with or without information on
BMD and provide estimates of the probability of fracture.
Models are available for 16 member states.
Austria, Belgium Denmark, Finland, Hungary and the UK
have the highest usage of FRAX. If Denmark is excluded
because of exceptionally high uptake, this amounts to an
average of 4,800 tests/million of the general population
which is within the estimated service requirement for FRAX.
The uptake of FRAX is sub-optimal in the majority of EU
countries for which models are available.
Approved pharmacological interventions include
bisphosphonates, strontium ranelate, raloxifene, denosumab
and parathyroid hormone peptides (PTHs). These are widely
available but their use is restricted by reimbursement policies.
Full or near full reimbursement is available in a minority of
member states. In other countries reimbursement is partial or
restricted to individuals with a prior fracture or to women only.
Some countries that provide reimbursement exclude PTH.
Fracture prevention with generic alendronate in women
aged 50 years and older at high risk of fracture is cost-
effective in most Western countries. Other treatments are
cost-effective alternatives to no treatment, particularly in
patients that cannot take alendronate.
Compliance and persistence with treatment for osteoporosis
are poor; approximately 50 % of patients do not follow their
prescribed treatment regimen and/or discontinue treatment
within 1 year.
Measures to improve adherence will lead to more avoided
fractures and are cost-effective complements to currently
available treatments.
In all national treatment guidelines a case-finding approach
is suggested for patient identification. However, they vary in
terms of which risk factors are acknowledged, how fracture
risk should be assessed and how BMD measurements
should be used.
Notwithstanding the availability of guidelines, recommenda-
tions in national guidelines are not always implemented.
2.1 Introduction
In recent years, there has been a number of advances,
particularly in the measurement of BMD, the assessment
of fracture risk, the development of interventions that reduce
the risk of fractures and the production of practice guide-
lines. These advances have been extensively reviewed in an
earlier report [1] but relevant sections are summarised in the
present report to give the report appropriate context. A
particular focus of the chapter is to describe the manner in
which these advances have been applied in member states.
2.2 Use of BMD
The assessment of bone mass forms a cornerstone for the
general management of osteoporosis being used for diagno-
sis, risk prediction, selection of patients for treatment and
monitoring of patients on treatment [2].
In addition to categorising individuals as having or not
having osteoporosis (Chapter 1), a much more important use
of bone mineral measurement is to provide prognostic infor-
mation of future fracture risk [3, 4]. A further use is as a tool to
monitor changes in bone mass in a treated or untreated patient,
though this remains a somewhat contentious issue [5–7].
2.2.1 Availability of DXA
The requirement for assessing and monitoring the treat-
ment of osteoporosis in accordance with practice guide-
lines has been estimated at 10.6 DXA units per million
of the general population [8]. Several surveys have
indicated marked heterogeneity in the availability of
DXA in the EU [8, 9] and a recent survey, based on
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manufacturer sales, confirms this finding (Kanis J.A.
personal communication 2011). The survey indicated
that about 50 % of countries in the EU had the
recommended number of DXA machines for their pop-
ulation. It is important to note that the figures provided
do not distinguish machines dedicated in part or in full
to clinical research, or machines that lie idle or are
underutilised because of lack of funding. It is likely,
therefore, that a majority of countries are under-
resourced in the context of practice guidelines.
A further consideration is the uneven geographical
location of equipment, which is known to be problem-
atic in Italy, Spain and the UK. This inequity results in
long waiting times or long distances to travel or, in
many cases, no practical access at all. A recent audit
of the IOF [10] (an update of an earlier audit [9])
reported that the average waiting time among the EU
countries is 29 days but ranges from 0 to 6 months in
different countries. Within countries there may also be a
large range in waiting times, in some instances up to
1 year. The median waiting times are shown in Fig. 12.
There is no clear relationship between waiting times and
the availability of DXA. For example, the average
waiting time in Italy is reported to be 83 days, though
the availability is high (18.6 machines/million of the
general population). Conversely, there is no waiting
time in Bulgaria where the provision of DXA is low.
The latter observation presumably reflects the fact that
the few machines available are only used to service
specialised departments and that BMD assessments are
unavailable to the vast majority of the population at
risk. The disparity between the availability of equipment
and waiting time identifies a high heterogeneity in the
use of BMD to assess osteoporosis.
Reimbursement for DXA scans varies widely between
member states both in terms of the criteria required and
level of reimbursement awarded but only a minority of
countries (11/27) provided full reimbursement under any
circumstances in 2008. Since then reimbursement poli-
cies have improved and 18 countries offered uncondi-
tional reimbursement in 2013 [10] (Table 6). In others,
reimbursement or partial reimbursement is limited and
usually dependent on physician referral for approved
indications, sometimes restricted to criteria that do not
satisfy the requirements of good clinical practice. An
example is seen in Bulgaria (and incidentally in Swit-
zerland) where reimbursement is only offered if the
BMD test turns out to be positive (i.e. shows osteopo-
rosis). The cost of DXA also varies widely (Table 6)
and bears little relationship to the wealth of the nation
or to the availability of DXA machines.
Fig. 11 DXA units/million of the general population in 2010 based on
sales of DXA in the EU supplied by manufacturers (Kanis J.A. per-
sonal communication, 2011)
Fig. 12 Average waiting time for a DXA assessment by EU country [10]
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Table 6 The number and provision of central DXA units available in the EU27 (Data on reimbursement and waiting time [10])
* average of range; adata; ddays
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2.3 Assessment of fracture risk
Although the diagnosis of the disease relies on the quantitative
assessment of BMD, which is a major determinant of bone
strength, the clinical significance of osteoporosis lies in the
fractures that arise. In this respect, there are some analogies
with other multifactorial chronic diseases. For example, hy-
pertension is diagnosed on the basis of blood pressure, where-
as an important clinical consequence of hypertension is stroke.
Because a variety of non-skeletal factors contributes to frac-
ture risk [4, 28], the diagnosis of osteoporosis by the use of
BMD measurements is at the same time an assessment of a
risk factor for the clinical outcome of fracture. For these
reasons there is a distinction to be made between the use of
BMD for diagnosis and for risk assessment.
2.3.1 Assessing risk with BMD
The use of bone mass measurements for prognosis depends
upon accuracy. Accuracy in this context is the ability of the
measurement to predict fracture. As reviewed previously,
many prospective population studies indicate that the risk for
fracture increases by a factor of 1.5 to 3.0 for each SD
decrease in BMD [29]. The ability of BMD to predict fracture
is comparable to the use of blood pressure to predict stroke,
and significantly better than serum cholesterol to predict myo-
cardial infarction [3, 4]. The highest gradient of risk is found at
the hip to predict hip fracture where the fracture risk increases
2.6 fold for each SD decrease in hip BMD.
Despite these performance characteristics, it should be
recognised that just because BMD is normal, there is no
guarantee that a fracture will not occur—only that the risk
is lower. Conversely, if BMD is in the osteoporotic range,
then fractures are more likely, but not invariable. The
principal difficulty is that BMD alone has high specificity
but low sensitivity, so that the majority of osteoporotic
fractures will occur in individuals with BMD values above
the osteoporosis threshold [30–34]. The low sensitivity is
one of the reasons why widespread population-based
screening is not recommended in women at the time of
the menopause.
2.3.2 Clinical risk factors (CRFs)
The performance characteristics of the test can, however,
be improved by the concurrent consideration of risk
factors that operate independently of BMD. A good
example is age. The same T-score with the same tech-
nique at any one site has a different prognostic signifi-
cance at different ages [35, 36], indicating that age
contributes to risk independently of BMD (Fig. 13).
Thus, the consideration of age and BMD together in-
creases the range of risk that can be identified.
There are, however, a large number of additional risk
factors that provide information on fracture risk indepen-
dently of both age and BMD. A caveat is that some risk
factors may not identify a risk that is amenable to
particular treatments, so that the relationship between
absolute probability of fracture and reversibility of risk
is important [37]. Liability to falls is an appropriate
example where the risk of fracture is high, but treatment
with agents affecting bone metabolism may have little
effect [38].
Over the past few years a series of meta-analyses has
been undertaken to identify internationally validated inde-
pendent CRFs to be used in case finding strategies with or
without the use of BMD. These are summarised in Table 7
[39] and form the input to compute fracture probability with
FRAX. Detailed considerations of the CRFs used have been
recently reviewed [1, 40].
Fig. 13 The relationship between BMD at the femoral neck
expressed as a T-score and 10-year hip fracture probability in
women from Sweden according to age. For any given T-score,
the probability of fracture is higher with increasing age [36], with
kind permission from Springer Science and Business Media
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2.4 FRAX®
FRAX models are algorithms that integrate the weight of
CRFs for fracture risk, with or without information on
BMD. They were developed by the WHO Collaborating
Centre for Metabolic Bone Diseases at Sheffield, UK and
launched in 2008 [28]. Femoral neck BMD or the T-score
equivalent may be optionally input. The FRAX tool
(www.shef.ac.uk/FRAX) computes the 10-year probability
of hip fracture or a major osteoporotic fracture. A major
osteoporotic fracture is a clinical spine, hip, forearm and
humerus fracture.
FRAX computes a fracture probability. The probabil-
ity of fracture depends upon age and life expectancy as
well as the current relative risk. Thus, where the risk of
death is high, the probability of fracture will decrease
for the same fracture hazard. The Poisson regression
models used in the development of the FRAX model
allow the interaction between the identified CRFs, frac-
ture, death and the time parameter to be incorporated.
For example, they account for the impact of smoking or
low BMI not only on fracture risk but also on the risk
of death. The latter is a unique feature compared to
other fracture prediction tools [41, 42].
Table 7 Clinical risk factors used for the assessment of fracture probability with FRAX [28]
Arch Osteoporos (2013) 8:136 Page 21 of 115, 136
Facture risk and mortality differ markedly in different
countries so that FRAX models are calibrated to the
epidemiology of specific countries where appropriate
information is available. In Europe, models are available
for Austria, Belgium, Czech Republic, Finland, France,
Germany, Hungary, Italy, Malta, Netherlands, Norway,
Poland, Romania, Spain, Sweden, Switzerland and the
UK. The 10-year probability of a major osteoporotic
fracture for a 65-year old man or woman with previous
fracture, a femoral neck T-score of −2.5 SD, a BMI of
25 kg/m2 and no other risk factors for various European
countries is shown in Fig. 14. As in the case of hip
fracture, there is a marked heterogeneity of fracture
probability in the different European countries. Also,
where the probability is high in men, it is high in
women and vice versa. Unlike fracture risk, the differ-
ence in fracture probability between men and women is
not marked. This is because, in the example provided,
BMD is used in the calculation of probability. In men
and women of the same age and with the same BMD,
fracture risk is similar [43]. The somewhat higher prob-
abilities in women are due to the longer life expectancy
in women compared with men.
Like any algorithm, FRAX has a number of limita-
tions. For example, several of the CRFs used take no
account of dose-response, but rather represent an av-
erage dose or exposure. Thus, there is good evidence
that the risk associated with smoking [44, 45], excess
alcohol consumption [46], and the use of glucocorti-
coids [47, 48] increases with increasing exposure, as
does the number of prior fractures [40, 49, 50]. On the
other hand, the algorithms are easy to use and their
simplicity is appropriate for primary care.
The application of FRAX to clinical practice demands
a consideration of the fracture probability at which to
intervene, both for treatment (an intervention threshold)
and for BMD testing (assessment thresholds). Probability-
based intervention thresholds have been developed for
Europe in a generic sense [51, 52], but also for individ-
ual countries including Canada, Germany, Japan, Sweden,
Switzerland, the UK and US [39, 53–56]. The potential
application of the UK guidance for the identification of
individuals at high risk of fracture, developed by the
National Osteoporosis Guideline Group (NOGG)
(www.shef.ac.uk/NOGG), to other EU countries is devel-
oped in subsequent chapters.
2.4.1 Utilisation of FRAX
FRAX was launched in 2008, at which time models
were available for Austria, France, Germany, Italy,
Spain, Sweden and the UK. Since then, nine addition-
al models have been added so that 16 of the 27 EU
member states are serviced. More models are under
development. The web based usage of the models is
shown in Table 8 which shows considerable heteroge-
neity in uptake. Belgium, UK, Luxembourg, Sweden
and Ireland have the highest usage of FRAX. These
data underestimate the use of FRAX by an uncertain
amount due to the availability of FRAX on bone
densitometers. The FRAX calculations are not effected
through the web site. In addition, hand held calcula-
tors are used in several countries, particularly in Po-
land. In Germany, probability based fracture risk
assessment comprises a component of National guide-
lines, but is not FRAX based.
Fig. 14 Ten-year probability of a major osteoporotic fracture (%) for a
65-year old man or woman with previous fracture, a femoral neck T-
score of −2.5 SD and BMI of 25 kg/m2 and no other risk factors
according to FRAX in different European countries
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Table 8 FRAX calculations by country of origin (URL) between November 2010 and December 2011 [Google Analytics]
a
Alternate model available;
b
Hand held model available
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With these caveats, it is appropriate, but difficult, to
compare the current uptake of FRAX with the targets that
might be required for adequate service provision. In the
case of DXA, the requirements for risk assessment were
estimated at 3–5 DXA units/million of the general popu-
lation in the year 2000 [8]. With an average of 1250
tests/unit/year this equates to a requirement of 3750–
6250 tests/million of the population/year. In Belgium
which has the highest uptake of FRAX in the EU, the
use of FRAX on the web site amounted to 51,860 calcu-
lations in one year for a population of 10.7 million,
equivalent to 473 tests/million (Fig. 15 and Table 8). Thus
the usage of FRAX is less than the estimated optimal
requirements for DXA by a large amount. In many prac-
tice guidelines (e.g. the UK), the use of FRAX should
outstrip the use of DXA. These considerations suggest
that uptake of FRAX is sub-optimal in all EU countries,
including those for which models are available.
2.5 Treatment of osteoporosis and prevention of fracture
In recent years there have been significant advances in the
management of osteoporosis, particularly with respect to the
development of pharmacological interventions to reduce
fracture risk. These are summarised below and more de-
tailed accounts are given in the review of the EU5 countries
[1] and the European guidelines for glucocorticoid-induced
osteoporosis [52].
2.5.1 General management
General management includes the avoidance of modifiable risk
factors such as smoking and excessive alcohol intake. Assess-
ment of the risk of falls and their prevention is important, espe-
cially in the elderly. An increased likelihood of falls can arise
from numerous age- and disease-related factors. Some of these
factors, such as impaired vision can bemodified and there is good
evidence that prompt treatment of cataracts reduces falls risk [57].
Other disease processes are more difficult to manage including,
for example heart disease, dementia, stroke and other neurolog-
ical diseases. Some medications, especially sedatives, can impair
balance and are significant risk factors for fractures. Environmen-
tal factors that can precipitate a fall include slippery or uneven
flooring, carpet edges and poor or inadequate footwear. Fur-
ther, where possible, drugs that induce accelerated bone loss
should be avoided or the minimum effective dose titrated.
Immobility is a strong risk factor for osteoporosis [58].
Maintenance of mobility is therefore important. It is not
known what constitutes the optimal exercise programme to
maintain skeletal mass in health or disease but exercise can
also improve posture and balance to protect against both
falls and fractures [59].
Fig. 15 FRAX calculations by URL source Nov 2010-Nov 2011 [Google Analytics]
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Correction of nutritional deficiencies, particularly of
calcium, vitamin D and protein, are advised. Intakes of
at least 1,000 mg/day of calcium, 400–800 IU of vita-
min D and of 1 g/kg body weight of protein are widely
recommended [60, 61]. Calcium, vitamin D and the
combination are commonly used in patients as a prima-
ry therapeutic agent, particularly in combination with
other therapeutic agents.
Calcium supplements and vitamin D are widely available
in all EU countries but guidelines regarding their use and other
lifestyle advice are not universally provided. The provision of
government endorsed public health programmes on nutrition
and lifestyle is even lower and available in only 7 member
states (Bulgaria, Finland, France, Italy, Luxembourg, Sweden
and the UK) [10].
2.5.2 Major pharmacological interventions
Approved pharmacological interventions include
bisphosphonates, strontium ranelate, raloxifene,
denosumab and parathyroid hormone peptides [1]. In-
terventions that are approved for the prevention and
treatment of osteoporosis in Europe are shown in Table
9. Most of these are approved only for the treatment of
postmenopausal osteoporosis. However, alendronate, eti-
dronate, risedronate zoledronic acid and teriparatide are
also approved for the prevention and treatment of
glucocorticoid-induced osteoporosis in Europe [52] and
alendronate, risedronate, zoledronic acid, strontium
ranelate and teriparatide are approved for the treatment
of osteoporosis in men.
Table 9 Pharmacological interventions used in the EU for the prevention of osteoporotic fractures [1]
a Registered but not marketed widely (Germany and Spain)
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All these interventions have been shown to reduce
the risk of vertebral fracture when given with calcium
and vitamin D supplements. Some have been shown to
also reduce the risk of non-vertebral fractures and some
specifically, hip fractures. Of the available options,
alendronate, risedronate, zoledronic acid, denosumab
and strontium ranelate have been demonstrated to re-
duce vertebral, non-vertebral and hip fractures [38, 62–
72] (Table 10). Because of this broader spectrum of
anti-fracture efficacy these agents are generally
regarded as preferred options in the prevention of frac-
tures in postmenopausal women. This distinction is
important because once a fracture occurs, the risk of a
subsequent fracture at any site is increased independent
of BMD [73], and hence an intervention that covers all
major fracture sites is preferable.
Since there have been no head-to-head studies with
fracture as the primary outcome, direct comparison of
efficacy between agents is not possible. However, the
reduction in vertebral fracture rate has generally been
between 50 and 70 %; whereas the magnitude of
reduction in non-vertebral fracture, where demonstrat-
ed, has generally been smaller and in the order of 15
to 25 %. This difference in effect on different fracture
outcomes is likely to reflect, at least in part, the
importance of falls in the pathogenesis of these frac-
tures but may also result from differences in the ef-
fects of the treatments on cortical and cancellous
bone.
Reduction in fracture risk has been shown to oc-
cur within 1 year of treatment for bisphosphonates,
strontium ranelate and denosumab. This is particu-
larly important in the case of vertebral fractures,
since after an incident vertebral fracture there is a
20 % risk of a further fracture occurring within the
next 12 months, emphasizing the importance of
prompt treatment once a fracture has occurred [49,
74, 75].
Although pharmacological interventions are licensed
for use, uptake within the EU is restricted, particularly
with regard to reimbursement policies (Table 11) [9,
10]. Full or near full reimbursement is available in a
minority of member states. There is no reimbursement
in Malta. In other countries reimbursement is partial or
rest r icted to individuals with a prior fracture
(Germany) or to women only (Netherlands). Some
countries with reimbursement exclude PTH (e.g. Italy,
Sweden).
Table 10 Spectrum of anti-fracture efficacy of interventions approved in Europe [39]
NAE: not adequately evaluated
*In subsets of patients (post-hoc analysis)
PTH: parathyroid hormone
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2.5.3 Future developments in the treatment of osteoporosis
A number of new approaches is being explored for the
prevention of fractures in postmenopausal women [76].
These include new treatment modalities including anti-
bodies to Wnt antagonists e.g., sclerostin [77], cathep-
sin K inhibitors [78], transdermal PTH peptide
formulations [79], and drugs that act on calcium
Table 11 Available medical interventions and reimbursement policies [9, 10]
-Not available or not reimbursed
a Not all bisphosphonates available
b Only if prescribed by a specialist
PTH: parathyroid hormone
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sensing receptors [80]. In addition, there is growing
interest in the use of sequential therapy, using anti-
resorptive drugs to maintain the benefit of anabolic
agents, and using mild anti-resorptives after a period
of treatment with potent anti-resorptive drugs such as
denosumab.
2.5.4 Vertebroplasty and balloon kyphoplasty
Vertebroplasty and balloon kyphoplasty are options for the
management of acute vertebral fractures [81]. Vertebroplasty
consists of the transpedicular placement of bone cement into
fractured vertebral bodies, whereas in balloon kyphoplasty a
balloon is introduced into the fractured vertebra and inflated to
restore vertebral height. Subsequently, the balloon is deflated
and the space created is filled with bone cement. Both ap-
proaches have been shown to reduce pain and improve func-
tional ability significantly when compared to non-surgical
management in patients with acute symptomatic vertebral
fractures [82–84]. Balloon kyphoplasty appears to be superior
to vertebroplasty with respect to restoration of vertebral height
and reduction of spinal deformity, although the clinical and
functional significance of the relatively small differences
remain to be established.
In the majority of studies, these procedures were compared
to non-surgical management. However, in two recent random-
ized controlled studies, vertebroplasty was compared to a
placebo procedure in which the various stages of
vertebroplasty were mimicked but without injection of ce-
ment. Neither of these studies was able to demonstrate a
beneficial effect of vertebroplasty over placebo on pain, func-
tional ability or quality of life [85, 86]; a recent meta-analysis
of individual patient data from these studies failed to show an
advantage of vertebroplasty over placebo for participants with
recent onset fracture or severe pain [87]. The follow-up period
of these studies was relatively short (1 month and 6 months,
respectively) and it is possible that the long-acting local an-
aesthetic injected in the placebo group might have provided
some pain relief in the placebo group. No placebo-controlled
trials have been conducted for balloon kyphoplasty.
In a recent study, vertebroplasty was found to have a
higher rate of procedure-related complications than bal-
loon kyphoplasty and a higher rate of cement leakage,
which may sometimes result in neurological symptoms
[88]. A potential concern for both procedures is that the
risk of compression fractures in vertebrae adjacent to
the operated vertebra might be increased and further
long-term studies are required to address this issue.
The results of studies so far reported indicate a similar
incidence of new vertebral fractures in women who
have undergone balloon kyphoplasty or vertebroplasty
when compared to non-surgical management but longer
term data are required. A recent study from the US
Medicare database found the relative risk of mortality
for kyphoplasty patients was 23 % lower than that for
vertebroplasty patients (adjusted HR=0.77, p<.001)
[89].
2.5.5 Fracture liaison services
Fracture liaison services, also known as osteoporosis co-
ordinator programmes and care manager programmes, pro-
vide a system for the routine assessment and management of
postmenopausal women and older men who have sustained
a low trauma fracture [90–94]. Although the importance of
an incident fracture as a risk factor for further fracture is well
recognised, the majority of patients presenting with a low
trauma fracture do not receive appropriate assessment and
treatment in the setting of standard hospital care. Fracture
liaison services address this need through a systematic ap-
proach to identifying the vast majority of such individuals
and assessing their risk of further fractures and the need for
treatment. Most fracture liaison services are based in sec-
ondary care although models in primary care have also been
described. A dedicated co-ordinator, often a nurse, working
closely with the patient, primary care physician, orthopaedic
and trauma department and osteoporosis and falls service is
central to the development of a successful service. An
example of the structure of a fracture liaison service is
shown in Fig. 16.
Fig. 16 Example care team: The operational structure of a UK-based Fracture Liaison Service (FLS) [95, 96]
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The clinical and cost-effectiveness of fracture liaison
services has been demonstrated in several centres [97–
101]. In an analysis of data collected over 8 years in Glas-
gow it was estimated that the service prevented 18 hip
fractures and saved £21,000 per 1000 patients [102].
Use of a systematic coordinator approach in the Kaiser
Permanente Healthy Bones Program was associated with
a 40 % reduction in hip fractures [103]. The health
economic analyses that have been published so far have
shown that osteoporosis management programmes are a
cost-effective intervention for the prevention of fractures
[101, 102, 104, 105]. A fracture liaison service in
Sydney, Australia, reduced the risk of re-fracture of
the hip by 80 %, improved quality of life and was
associated with an incremental cost-effectiveness ratio
(ICER) versus standard care of 17,291 Australian dol-
lars per QALY gained [104].
2.6 Cost-effectiveness of pharmaceutical interventions
The osteoporosis market is today dominated by
bisphosphonates, particularly alendronate, which has be-
come the first-line choice in many countries given its
proven efficacy and low price. Bisphosphonates are
generally found to be cost-effective in women with
osteoporosis, regardless of whether or not the perspec-
tive is societal and if the modelling horizon is lifetime
or shorter [106].
A pan-European study from 2004 estimated the
cost-effectiveness of branded alendronate in nine
countries [26]. In this study alendronate was shown
to be cost-saving compared with no treatment in wom-
en with osteoporosis (with and without previous ver-
tebral fracture) from the Nordic countries (Norway,
Sweden, and Denmark). The cost-effectiveness of
alendronate compared to no treatment was also within
acceptable ranges in Belgium, France, Germany, Italy,
Spain and the UK. However, with the rapid decline in
the price of the generic alendronate, analyses based on
a branded drug price have become obsolete and would
require an update. For example, in the above men-
tioned study the annual price of alendronate varied
between €444/year (UK) to €651/year (Denmark).
The current drug price for alendronate is less than
€300/year in all countries and as low as €18/year in
the UK. Revisiting the analysis using these prices
would markedly improve the cost-effectiveness of ge-
neric alendronate.
In a more recent study from 2008 [107], the cost-
effectiveness of alendronate compared with no treatment
using a generic price in the UK was assessed by using
the FRAX algorithm for fracture risk estimation.
Alendronate was in this analysis priced at £95/year
and could be considered cost-effective in most age and
risk groups (Table 12).
The cost-effectiveness of a range of treatments has also
been evaluated in women with a BMD value meeting or
exceeding the threshold of osteoporosis. As seen in Table
13, the cost-effectiveness of alendronate compared with
Table 12 Cost-effectiveness of alendronate (cost (£000)/QALY gained) in
UK women with clinical risk factors according to age and T-score for
femoral neck BMD [107]. A cost of less than £20–30,000/QALY gained
is considered to be cost-effective
c.s. = cost-saving
Arch Osteoporos (2013) 8:136 Page 29 of 115, 136
no treatment was better than for the alternatives [107].
This is mainly driven by the drug price rather than differ-
ences in efficacy between treatments. Recent studies sug-
gest, however, that some generic formulations are less
well tolerated than the branded product which may have
an adverse effect on cost-effectiveness [108]. This consid-
eration aside, the study supports the view that alendronate
should be considered as a first line intervention, at least in
a UK setting. Nevertheless, cost-effective scenarios were
found for treatments other than alendronate, providing
credible alternative options for patients unable to take
alendronate. Similar conclusions have also been reached
in separate studies for most second line treatments [106,
109–114]. There are differences, however, in the spectrum
of efficacy of these alternatives across different fracture
sites that will determine their suitability in the clinical
management of individuals.
With the advent of treatments directed to individuals at
high risk it is appropriate to consider the fracture probability
at which interventions become cost-effective [115]. This has
been explored for the use of alendronate [107, 116]
risedronate [114], denosumab [113], raloxifene [117] and
strontium ranelate [111]. In the case of generic alendronate
treatment compared to no treatment was found to be cost-
effective at a 10-year probability of a major fracture of 7.5 %
in a UK setting (Fig. 17). The threshold probability at which
treatment became cost-effective was higher with other treat-
ments than for alendronate, related in large part to the higher
cost of intervention. For example, at a WTP of £20,000 per
QALY, treatment with risedronate was cost-effective at a
probability threshold of 19 % compared with a threshold of
7 % with generic alendronate.
When considering the body of published evidence, fracture
prevention with alendronate in women at elevated risk of
fracture older than 50 years is cost-effective in most western
countries. Cost-effectiveness improves further in patients with
additional risk factors. Fracture risk at a given T-score is
similar in men and women [28], the effectiveness of interven-
tion in men is broadly similar to that in women at equivalent
risk [43], and the cost and disutility of fractures is similar in
men and women [118, 119]. For these reasons the cost-
effectiveness of treating men is broadly the same as for wom-
en at a given absolute risk of fracture [116, 120].
Table 13 Cost-per QALY gained (£) of various drugs compared to no treatment in women aged 70 years in the UK [51]
Fig. 17 Correlation between the probability of a major osteoporotic
fracture and cost-effectiveness at the age of 50 years in women from
the UK (BMI set to 26 kg/m2). Each point represents a particular
combination of BMD and CRFs. The horizontal line denotes the
threshold for cost-effectiveness (a willingness to pay of
£20,000/QALY gained) (Kanis et al. with permission from Elsevier
[107])
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2.7 Adherence, compliance and persistence
There is a wide variety of definitions for adherence in the
literature. The term compliance is widely used, but it has been
argued that the term implies “obedience to doctors” and that it
should be termed in a way that also includes the active choice
of the patient [121]. In line with this view, a number of
alternative terms have been proposed: adherence, patient co-
operation, therapeutic alliance or concordance, referring to the
agreement between patient and physician [122–125]. For the
purpose of this report the terms compliance and persistence
were used to define the following of dosing instructions and
the time on treatment, respectively. The term adherence was
used as a general term encompassing both of these concepts.
Adherence is one of the rising challenges in osteoporosis
treatment, since suboptimal adherence results in suboptimal
clinical effects such as inadequate fracture prevention. Adher-
ence is not equal in all drug administration but depends on
different drug characteristics, discussed below in this section,
and there are thereby factors that can be improved in the
development of new drugs. Due to its impact on fracture risk,
adherence should be considered in cost-effectiveness models.
2.7.1 Measurements of adherence
The methods available for measuring adherence are usually
broken down into direct and indirect methods of measure-
ment. Each method has advantages and disadvantages, and no
method is considered the gold standard [126, 127]. Examples
of direct measures of adherence include directly observed
therapy, measurement of concentrations of a drug or its me-
tabolite in blood or urine, and detection or measurement in
blood of a biological marker added to the drug formulation.
Indirect methods of measurement of adherence include asking
the patient how easy it was to take the prescribed medication,
performing pill counts, ascertaining rates of refilling prescrip-
tions, collecting patient questionnaires, using medication
event monitoring systems or asking the patient to keep a
medication diary [128].
Whilst clinical trials remain the gold standard for measur-
ing fracture reduction, the high internal validity required to
demonstrate efficacy comes at the expense of external validity.
The results of such trials may therefore generalize poorly to
clinical practice [124, 129] since the benefits obtained in
practice might fall short of the anticipated benefits indicated
by clinical trials. Another factor important to consider when
measuring adherence is that patients who know they are
observed alter their behaviour, and thus prospective studies
of patient cohorts can lead to overestimations of adherence.
Therefore, persistence and compliance of medication is often
measured retrospectively using claims data. Such data also has
the advantage of including a very high number of patients so
that they can be used to measure the relationship between
adherence and clinical efficacy. However, the results from
these studies are very general, and usually report on the
number of prescriptions filled over time. Compliance in terms
of how and if drugs are actually taken cannot be studied with
this method. These retrospective database studies often pro-
duce two types of adherence estimates:
1) Persistence, defined as either the time to treatment discon-
tinuation or as the proportion of patients that at a certain time
point still fill prescriptions without a gap in refills longer
than an allowed period of time (e.g., 30, 60 or 90 days).
2) Compliance, defined as medication possession ratio
(MPR). MPR is usually defined as the number of days of
medication available to the patient, divided by the number
of days of observation. Estimates of MPR should be
interpreted with caution since its meaning differs with the
definition of days of observation. MPR measures only the
frequency and length of refill gaps if the observation time
is defined to be the same as a patient’s total time on
treatment [130]. If days of observation is a predefined time
period (e.g., 24 months) [131], MPR becomes a composite
estimate of persistence and compliance. Although the
MPR provides insight into the availability of medication,
it does not provide information on the timeliness and
consistency of refilling. An MPR >80 % is often used as
a threshold for high adherence, where improved clinical
outcomes can be observed [131–133]. However, this
threshold originates from a blood pressure control study
[134] and has been criticised for being arbitrary when
extrapolated to other diseases [135].
MPR can also be measured in prospective studies, where
patients report their own drug consumption. These self-
reported studies however more commonly report on general
compliance and patients also have the possibility to report
on adherence to administration protocol. It should be noted
that self-reported studies often result in better compliance
than parallel database studies [136, 137].
Patient education and nurse-led monitoring early in the
course of treatment have been shown to improve compliance
[138]. It has not been established whether monitoring by mea-
surement of biochemical markers of bone turnover or BMD
provides additional benefits [5, 6, 139]. The determinants of
low persistence and compliance to treatment are not well un-
derstood. Research suggests that several factors are important,
including dosing requirements and frequency, adverse events,
the patient-physician relationship, and patient inability to detect
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symptomatic improvement [135, 140–143]. Retrospective stud-
ies indicate that weekly dosing regimens are associated with
better persistence than daily regimens [143]. New treatments
have quarterly (i.v. ibandronate), 6-monthly (denosumab), or
annual (zoledronate) dosing. Theoretically, this type of admin-
istration should have potential to improve adherence. However,
to what extent increased use of these drugs will improve adher-
ence and lead to fewer fractures in clinical practice is currently
not known. This will be an important issue to address in future
studies when sufficient real world data become available.
2.7.2 Adherence in a real world setting
Compliance and persistence with treatment for osteoporosis
in clinical practice are poor; approximately 50 % of patients
do not follow their prescribed treatment regimen and/or
discontinue treatment within 1 year [144]. Adherence to
anti-fracture treatment has been studied extensively.
Kothawala [145] presented a meta-analysis of adherence to
osteoporosis medication. This review compares results from
self-reported as well as database studies and concludes that
about one-third to half of all patients on osteoporosis med-
ication do not take their medication as directed. The pooled
persistence data resulted in persistence rates of 52 % for
treatments lasting 1–6 months, 50 % for treatments lasting
7–12 months and 42 % for treatments lasting 13–24 months.
2.7.3 Adherence and anti-fracture efficacy
Poor adherence has been shown to be associated with reduced
anti-fracture efficacy when expressed both as MPR [131] and as
persistence [130, 146]. Figure 18 shows an analysis from the
Swedish Adherence Register Analysis (SARA) study depicting
the relation between time on treatment and fracture risk in 37,394
bisphosphonate-treated patients observed for 36 months [130].
Themagnitude of effect may be overestimated since patients who
fail to comply with placebo have poorer health outcomes than
compliant patients [147, 148]. In the context of osteoporosis,
fracture risks have been reported to be higher and BMD lower
in non-persistent patients taking placebo comparedwith persistent
patients in the placebo wing of an intervention study [149].
Because osteoporosis is an asymptomatic disease where only a
fraction of the treated patients will sustain a fracture, large sam-
ples of patients are needed to detect differences in fracture rates
between patients with high and low adherence to medication.
Furthermore, two systematic reviews report on the link be-
tween adherence and anti-fracture efficacy. Ross et al. report that
both compliance and persistence are important factors for opti-
mal fracture prevention [150]. Their study points to the possi-
bility of persistence being evenmore important than compliance
in the effect on fracture risk; the meta-analysis showed that
fracture risk increases by 30 % with non-adherence and by
30–40 % with non-persistence. A review and meta-analysis by
Imaz et al. focuses on adherence to bisphosphonates and the
impact of poor compliance on fracture risk [151]. The
noncompliant patients were estimated to have a 46 % higher
fracture risk compared to highly compliant patients. The highest
impact of compliance on fracture risk was noted for vertebral
fractures, and was higher than that seen for hip fractures.
2.7.4 Cost-effectiveness and adherence
Health economic modelling of anti-fracture therapies is a
thoroughly researched area, and many publications on the
topic are available. However, adherence is seldom included
in the cost-effectiveness models. Poor adherence is commonly
believed to have little impact on cost-effectiveness in clinical
practice, since poor adherence affects cost as well as out-
comes. Also of relevance is that with poor adherence fewer
patients will be properly treated, and thus fewer fractures
prevented, which is the principal goal of treatment. Cost-
effectiveness analysis is also important in this context since
future improvements in fracture prevention may come not
only from more efficacious treatments but also through im-
proved drug delivery and adherence [152]. Thus the prices,
costs, and cost-effectiveness of these new alternatives need to
be compared with the present alternatives in clinical practice.
From a health economic perspective, high adherence is
particularly important when treating high-risk populations.
Cost-effectiveness of treatments that potentially confer high
adherence is sensitive to assumptions regarding the relation
between adherence and residual effect after stopping treat-
ment and drug-effect reductions from poor compliance.
Modelling studies of denosumab (6-monthly dosing) [113]
and zoledronate (12-monthly dosing) [153] have indicated that
improving treatment adherence is likely to be cost-effective.
The health benefits of improved adherence are often partially
offset by increased intervention costs that are associated with
the improved drug-taking behaviour. Nonetheless, adherence
Fig. 18 Relative risk (RR) of 2-year fracture incidence (reference:
<1 month of treatment) [130]
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is likely to be associated with added value for the healthcare
system because more fractures will be avoided [152, 154].
To summarise, adherence to osteoporosis treatment is
suboptimal and associatedwith reduced anti-fracture effectiveness
in clinical practice. The treatment gap in the management of
osteoporosis in Europe is partly caused by insufficient case find-
ing, but also in part by suboptimal treatment adherence. Besides
improved case finding, improved adherence to treatment would
increase treatment penetration in high risk populations and would
likely be associated with improved outcomes in clinical practice.
Much of the data discussed above come from outside
EU27 and given that data on adherence differs between re-
gions and people with different ethnicity [155], it is impor-
tant to study adherence in the European Union, and to assess
inter country variation. The pattern of data availability in
different countries is also of interest to identify future re-
search needs. A systematic literature review was performed
to assess the adherence to pharmaceutical treatment of oste-
oporosis in clinical practice in the EU27. The results are
presented as an appendix to this chapter (Appendix A).
2.8 National guidelines and reimbursement policies for
the management of osteoporosis in the EU
National guidelines for the assessment and treatment of
osteoporosis are available from the majority of member
states. Details of recent guidelines for the EU5 are
recently published [1, 28]. Their scope variously covers
post-menopausal women, men, glucocorticoid-induced
osteoporosis and population-based screening (Table 14).
With the exception of Germany and Italy, population-
based screening is not recommended. In Hungary, how-
ever BMD is offered free of charge to women aged
50 years or more, though the uptake is low. With the
exception of the UK, none of the guidelines are
underpinned by health economic analyses. In the UK,
the guidelines of the NOGG have been validated by an
economic analysis [107]. In the case of the National
Institute for Health and Clinical Excellence (NICE),
the guidance has been driven by cost-effectiveness
[156–158].
Table 14 Scope of guidelines for the assessment and treatment of osteoporosis in the EU [10]
PMW, postmenopausal women; GIO, glucocorticoid induced osteoporosis
nr, not recorded; na, not available
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Guidelines in 24 of the 25 countries covered the assessment of
fracture risk (the exception was the Czech Republic). The most
common tools for fracture risk assessment were age in 22/25
countries (exceptions were Lithuania, Slovakia and Sweden) and
bone mineral density (in all countries). The use of fracture risk
assessment algorithms was less consistent and noted in 18 coun-
tries. FRAX was the most widely used instrument though in
Germany the DVO tool was recommended [159]. In the UK
both FRAX and QFracture have been approved [160]. There are
some apparent anomalies in the recommendations over the use of
FRAX. In Italy and Spain, there are several guidelines from
different organisations that give divergent recommendations.
Guidelines in all 25 countries covered eligibility for treatment
with a general commonality of approach. Eligibility for treatment
depended on prior fracture (except Denmark and Sweden), age
(except Lithuania, Slovakia and Sweden) and BMD (all coun-
tries). As was the case for risk assessment tools, these provided
criteria for intervention in fewer (17/25) countries (Table 15).
Several counties reported incompatibilities between recom-
mendations for risk assessment or treatment with reimburse-
ment policy (Table 15). For example, guidelines recommended
the use of FRAXwhichwas not provided for in reimbursement
provision (Belgium, Poland, Romania and Slovakia), specific
treatments were recommended but not reimbursed (Poland,
Romania) and central DXAwas recommended for risk assess-
ment but other techniques (peripheral BMD and QCT) were
reimbursed (Lithuania). In Luxembourg, the BMD thresholds
for treatment differ from the criteria for reimbursement for
DXA. In other instances, guidelines recommended the use of
risk factors such as a prior fragility fractures but reimbursement
was solely dependent on BMD (Lithuania, Romania). With
regard to treatment, reimbursement was limited in time
(18 months) but treatment recommended on a long-term basis
(Lithuania). A problem inconsistently related to reimburse-
ment was that multiple guidelines gave conflicting recommen-
dations (Italy, Spain, and the UK).
Table 15 Summary of risk assessment and treatment criteria provided by treatment guidelines in the EU [10]
BMD - bone mineral density
n/a - not applicable
a Probability assessment, but not FRAX
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2.8.1 Compliance with guidelines
The Prospective Observational Study Investigating Bone
Loss Experience in Europe (POSSIBLE EU) is a longi-
tudinal, non-interventional cohort study with the objec-
tive to examine the use of osteoporosis medications in
EU5 [161]. The POSSIBLE EU included 3,402 women
that either were receiving or starting osteoporosis treat-
ment. Information regarding demographics, bone diag-
nosis (e.g., DXA), risk factors, co-morbidities and
concomitant medication was collected at baseline. Pa-
tients were followed up after 1 year. The data collected
in POSSIBLE EU provide interesting information on
how osteoporosis treatment is managed in clinical prac-
tice. An analysis of the baseline data showed that only
52 % of all patients had been evaluated by DXA and
68 % of these patients had osteoporosis and 32 %
osteopenia. 25 % of all patients had no DXA and no
prevalent fractures. There were also large variations
between countries, for example the proportion of pa-
tients that had osteoporosis (T-score<−2.5 SD), a prior
fracture and/or glucocorticoid therapy was 55 % in
Spain and 83 % in the UK.
These are interesting findings because they imply that
osteoporosis is managed somewhat differently in clinical
practice compared to national guidelines. It seems that
even though not specifically acknowledged and
recommended in several of the guidelines, physicians
in clinical practice do consider other risk factors such
as parental fracture, smoking and alcohol use in the
treatment decision. However, it also seems that guide-
lines have an impact in clinical practice. For example,
the UK which has more restricted recommendations
(i.e., the NICE guidelines) also has a notably higher
proportion of patients that fall under a more classical
definition of osteoporosis and high risk of fracture
based on BMD and prior fracture.
2.8.2 Imperfect health care practice
Notwithstanding a number of advances, particularly in
the diagnosis of osteoporosis, the assessment of fracture
risk, the development of interventions that reduce the
risk of fractures and the production of practice guide-
lines, a minority of patients at high fracture risk are
identified for treatment [162–165]. For example, a Ca-
nadian study of emergency department radiographs
found that only 55 % of vertebral fractures were men-
tioned in the radiology report [166]. In patients with a
fragility fracture, less than 20 % of individuals receive
therapies to reduce future fracture within the year fol-
lowing fracture [55, 162, 163, 167–169]. Paradoxically,
the therapeutic care gap is wider in the elderly in whom
the importance and impact of treatment is high; studies
have shown that as few as 10 % of such women with
fragility fractures receive any osteoporosis therapy
(oestrogens not considered) [162, 170, 171]. Further-
more, treatment rates following a fracture are lower for
those individuals who reside in long term care [163].
This contrasts with myocardial infarction, which over-
came a significant care gap over the past 15 years;
75 % of individuals now receive beta blockers to help
prevent recurrent myocardial infarction [172].
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Appendix A.
Literature review of recent adherence literature in the EU
In order to assess adherence to pharmaceutical pharma-
cological therapies for osteoporosis in clinical practice
in the EU27, a systematic literature review with the
following objective was performed: i) to identify and
describe recently published studies on adherence to os-
teoporosis medication in the EU27; and ii) if possible,
synthesise the findings.
1. Methods
Pubmed was searched for relevant articles published from
January 1 2006 to June 1 2011. Fixed search terms were
used to identify the relevant studies, both using free text and
Mesh terms: osteoporosis [Mesh], adherence [Mesh], adher-
ence, persistence, medication possession ratio, compliance
and drug schedule. Only articles in the English language
were considered.
Articles investigating adherence to pharmacological
treatment for primary osteoporosis in the EU 27 were
included in the review. Relevant treatments were defined
as bisphosphonates, hormone replacement treatment
(HRT), select ive estrogen receptor modulators
(SERMs), parathyroid hormone (PTH) peptides, stron-
tium ranelate and calcitonin. Articles were excluded if:
i) calcium and/or Vitamin D were the primary treat-
ments of interest; ii) the study had an interventional
design; iii) data were obtained from a non EU 27
country; iv) adherence, persistence or compliance were
not outcomes v) the article did not contain original data.
Articles were first screened based on their title and then
the abstract. Subsequently, the remaining articles were
reviewed in full text.
On the basis of these explicit criteria, search results were
independently reviewed by two reviewers trained in health
service research and differences in inclusion/exclusion of
articles were resolved through consensus agreement.
The definitions of compliance, persistence and adherence
vary among publications. Therefore, to ensure consistency,
we categorised reported measures according to pre-set def-
initions rather than using the definitions in the article. We
considered compliance as the correctness of drug intake in
terms of dose and frequency. Persistence was considered
as the time on treatment as well as the proportion of
patients being considered persistent at a specific time
point (e.g. at 1 year).
2. Results
The initial search resulted in 547 unique hits. The title
review excluded 241, leaving 306 articles for abstract re-
view. This process resulted in 75 articles to be studied in full
text. According to the pre-set definitions, 25 articles were
accepted for data abstraction (Fig. 19).
2.1 Study characteristics
Of the 25 studies, nine focused solely on persistence, six
focused solely on compliance, and ten assessed both out-
comes. The studies on persistence were more frequently
based on database derived data (n=15) than patient reported
data (n=3), with one study using both methodologies. The
studies on compliance showed a more even distribution of
database derived (n=6) and self-reported data (n=8) with
two studies using both methodologies (Table 16).
Fig. 19 Review process of articles on adherence to osteoporosis
treatment
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The most commonly studied drugs were bisphosphonates,
which were included in 21 out of 25 studies. Alendronate, a
bisphosphonate, was also the most common individual drug
reported on. Raloxifene, a SERM, was included in nine stud-
ies; strontium ranelate and teriparatide were included in two
studies while HRT and calcitonin were included in one study
each. The number of studies on specific classes and individual
treatments may reflect the prescription pattern and time of
availability of the different drugs in the EU.
2.2 Persistence
Persistence was measured in 19 of the 25 articles. According to
our definition both time to treatment discontinuation and pro-
portion of patients still on treatment at a predefined time from
treatment initiation were regarded as measures of persistence.
The definition of time to treatment discontinuation differed
among the studies. Four studies presented only median time to
discontinuation [1, 2, 5, 21]; two studies presented only mean
time to discontinuation [8, 22]; and one study presented both
outcomes [24]. It is notable that mean time to discontinuation
(231 days) differed from the median time to discontinuation
(267 days) in the study estimating both outcomes. Further-
more, the length of the permissible treatment gap differed
between the studies, ranging from 30 days to 45 days. Partially
reflecting these methodological differences, time to treatment
discontinuation ranged from 155 days in French women pre-
scribed daily alendronate or risedronate to 282 days in Belgian
women prescribed daily or weekly alendronate (Table 17).
Similarly, the definition of patients still on treatment at a
specified time point differed among studies. Five studies
defined patients still on treatment as patients that renewed
their prescription within a predefined gap from their last
prescription; three studies defined patients still on treatment
as patients having a medication possession ratio (MPR) at or
above 80 %; and one study presented estimates for both
definitions. It is notable that the estimate resulting from the
first definition (40 %) differed from the estimate resulting
from the second definition (49 %) in the article assessing both
methods. Furthermore, in the studies estimating the proportion
still on treatment using the predefined gap method, the per-
missible gap ranged from 30 days to 3 months, with one study
using a dynamic method with the permissible gap defined as
half of the dispensing time. Whilst the time points at which the
Table 16 Characteristics of the 25 articles included for data extraction
BP = bisphosphonates; SERM = selective estrogen receptor modulator; Str = Strontium Ranelate; HRT = Hormone replacement treatment
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proportion of persistent patients was estimated ranged from
3 months to 5 years, all nine studies estimated the proportion
of patients persistent at 12 months, with estimates ranging
from 30% in French women prescribedweekly alendronate or
risedronate to 58 % in Dutch women prescribed daily or
weekly alendronate or risedronate (Table 17). However, these
estimates may not be directly comparable reflecting the afore-
mentioned differences in definitions and methodology.
Table 17 Results from articles presenting database derived persistence results
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Table 17 (continued)
MPR = medication possession ratio; TTD = time to treatment discontinuation; P3m, P6m, P12m, P24m, P1y, P5y = persistent patients at 3 months,
6 months, 12 months, 24 months, 1 year, 5 years; BP = Bisphosphonates; Aln = Alendronate; Ris = Risedronate; Iba = Ibandronate; Eti =
Etidronate; Rlx = Raloxifene; Str = strontium ranelate; Ter = teriparatide; d = day; m = month
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Self-reported persistence was presented in four studies
(Table 18). Among these, time to treatment discontinuation
was the most frequent outcome, presented in three articles;
two studies estimated mean time to discontinuation and one
estimated median time to discontinuation, with estimate of
mean/median time to discontinuation ranging from
9.5 months in German women prescribed generic
alendronate [10] to 24 months in UK women prescribed
bisphosphonates [23]. As can be seen in the study by
Rossini et al. [15], patients appeared to discontinue treat-
ment at a higher rate during the first 6 months of treatment
than subsequently.
Self-reported and database derived persistence estimates
were combined to produce estimates of persistence at 6 and
12 months by Ziller et al. [11]. The results are presented in
Table 19.
Table 18 Results from articles presenting self-reported persistence results
Country Measure Mean or Paents Results Treatment Ref
TTD = time to treatment discontinuation; P3m, P6m = persistent patients at 3 months, 6 months, etc; Aln = alendronate; HRT = hormone replacement
treatment; Rlx = raloxifene; Cld = clodronate; Ris = risedronate; BP= bisphosphonates; disc = discontinued; *HRT, Rlx, Cld, Aln, Ris, and calcium+vitaminD
Table 19 Results from articles presenting combined database derived and self-reported persistence results
P6m, P12m, P24m, P36m = persistent patients at 6, 12, 24 and 36 months; Rlx = raloxifene; d = day
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2.3 Compliance
Compliance was measured in 16 of the 25 studies. Com-
pared to persistence, the studies of compliance were more
evenly distributed between databases and patient reports (six
database derived studies, eight patient reported studies, and
two studies using both approaches).
Database derived compliance was primarily measured as
medication possession ratio (MPR). Five of six studies
report point estimates of mean MPR [1, 2, 5, 7, 8] whereas
one used a cut-off point of MPR of 80 % to determine the
proportion compliant patients [11]. Among the studies
reporting point estimates of MPR, three reported MPR at
12 months [1, 2, 8] arguably producing a composite estimate
of persistence and compliance rather than an estimate of
compliance.
The point estimates of MPR ranged from 53 % for
French women prescribed daily bisphosphonates [8] to
85 % for French patients prescribed monthly ibandronate
[5] (Table 20). However, given the differences in
methodology among studies, the estimates may not be
directly comparable.
The characteristics and results of the studies pre-
senting self-reported compliance estimates are summa-
rized in Table 21. Since compliance encompasses many
aspects of drug intake, such as number of doses actu-
ally taken, correctness of timing of drug intake and
intake of drug according to specific instructions (e.g.
before a meal etc.), self-reported compliance reports
may be more informative than the database derived
estimates. However, the methodology for deriving self-
reported compliance estimates appeared less standard-
ised than for database-derived estimates, rendering com-
parisons of estimates of self-reported compliance more
challenging. Two studies used a validated instrument
designed to determine compliance—the Morisky
questionnaire—which gives the result as the Morisky
score [9, 20]. Blotman et al. used a test developed in
France [4] and Carr et al. performed a national survey
based on three validated questionnaires [23]. The
Table 20 Results from articles presenting database derived compliance results
MPR =medication possession ratio; Aln = alendronate; Str = strontium ranelate; Ris = risedronate; Iba = ibandronate; Eti = etidronate; Rlx = raloxifene;
m = month
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remaining studies presented self-reported MPR: one
study presented MPR as a point estimate [3] whereas
the four remaining studies presented the proportion of
patients above MPR cut-off points; among those the cut-off
points were set at 75 % in two studies [13, 14] and 80 % in
three studies [11, 12, 15].
The estimates of compliant patients derived using
questionnaires ranged from 48 % in UK for women
prescribed bisphosphonates [23] to 66 % in French
women prescribed bisphosphonates, raloxifene or stron-
tium ranelate. The proportion of patients who reported
an MPR above 75 or 80 %— indica t ing high
compliance—ranged from 61 % in Italian women pre-
scribed clodronate [15] to 93 % in Italian women pre-
scribed alendronate, risedronate or raloxifene [13]. In
the study reporting the point estimate of MPR, MPR
was reported at 93 % for women prescr ibed,
alendronate, risedronate, raloxifene or calcitonin [3].
The studies by Ziller et al. presented self-reported and
database derived compliance estimates which suggested that
patients overestimate their compliance [11, 12]. The results
from the self-reported part of the study were that 75 % and
Table 21 Results from articles presenting self-reported compliance results
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91 % of the German women participating in the study had
an MPR over 80 % for raloxifene and teriparatide, respec-
tively. When combined with the database derived estimates
of MPR, the estimates were modified to 32 % for raloxifene
and 80 % for teriparatide (Table 22).
2.4 Data synthesis
In order to produce meaningful estimates of persistence and
compliance in the EU27, the studies eligible for meta-
analysis should have a sufficient geographic spread. Having
assessed the methodologies used in the studies identified in
the review, we concluded that neither studies of persistence
nor compliance could be pooled to provide meaningful
estimates from an EU27 perspective.
To pool the estimates of persistence or compliance in
meta-analysis, the methodologies used in the selected stud-
ies must be sufficiently similar. Consequently, pooling da-
tabase derived and self-reported estimates would not be
appropriate in view of the different methodology used in
data collection.
For the studies estimating database derived persis-
tence, the seven studies presenting time to discontinua-
tion cannot be pooled with the studies presenting
persistence at a specified time point given that the out-
comes differ. When assessing the studies presenting
Table 21 (continued)
MPR =medication possession ratio; BP= bisphosphonate; Aln = alendronate; Ris = risedronate; Rlx = raloxifene; Ctn = calcitonin; Str = strontium ranelate;
Ter = teriparatide; HRT = hormone replacement treatment; Cld = clodronate; TEO = Test d’Evalution de l’Observance; *According to questionnaire
Table 22 Results from articles presenting combined database derived and self-reported persistence results
Country Measure Paents Result Treatment Ref
MPR = medication possession ratio; m = month
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time to discontinuation with respect to outcome (mean
or median) and permissible gap (number of days) a
maximum of three studies were eligible for pooling.
Similarly when assessing the studies reporting the pro-
portion of patients still on treatment at 12 months (the
most frequently reported time point) with respect to
outcome (MPR >80 % or patients refilling medication
within a pre-specified period) and length of permissible
gap, a maximum of four studies was eligible for
pooling.
Estimates of self-reported persistence were presented as
time to discontinuation in three studies and as either the
proportion of patients still on treatment or patients having
discontinued treatment in two studies, resulting in a maxi-
mum of three studies eligible for pooling.
For the studies estimating database derived compli-
ance, the six studies presenting a point estimate of
MPR cannot be pooled with the study reporting the
proportion of patients above a cut-off point (80 %)
for compliance, given that the outcomes differ. When
assessing the studies presenting a point estimate of
MPR with respect to outcome (MPR at 12 months or
MPR during entire period the patient remained on
treatment) a maximum of three studies were eligible
for pooling.
Estimates of self-reported compliance were either
reported using questionnaires (four studies, three different
questionnaires), cut-off point for MPR (four studies, two
different cut-off points) or point estimate of MPR (one
study). Consequently, a maximum of two studies was eligi-
ble for pooling, rendering analysis representative for the
EU-27 unfeasible.
2.5 Determinants and outcomes of adherence in reported
studies
The articles included in this review not only reported on
persistence and compliance. Some also reported on the
patient characteristics that could predict or correlate
with adherence behaviour. Carr et al. [23] described
factors associated with compliance and persistence to
bisphosphonate therapy. Adherence was better in pa-
tients with previous fractures and a longer history of
osteoporosis. Low persistence was correlated to con-
cerns about side effects of treatment. Side effects of
the gastro-intestinal (GI) tract with oral bisphosphonate
treatment was shown to be of considerable importance
for both compliance and persistence [17, 18]. Among
bisphosphonates, less frequent dosing was frequently
shown to associated with higher compliance and persis-
tence [1, 4–6, 8, 9, 15, 17–19, 22, 23, 25]. Weekly
administration was shown to outperform daily, and
monthly being better than weekly. None of the articles
indicate that less frequent dosing was associated with
increased adherence. However, the absolute numbers for
the respective outcomes differ substantially.
A number of articles also describe the consequence
of suboptimal adherence: lost clinical effect. Gallagher
et al. [25] reported a 22 % lower risk of hip and
femur fractures in current bisphosphonate users com-
pared to past users. Similar numbers are reported by
van den Boogaard et al. [19] when comparing fracture
risk in patients who are persistent with treatment for
1 year or not; they show that persistent use resulted in
a 26 % lower fracture rate. In a study of Dutch
women starting bisphosphonate treatment, Penning-
van Beest et al. [16] compared fracture risk in
noncompliant patients, defined as those patients hav-
ing an MPR<80 %. It was found that noncompliant
use was associated with a 45 % increased fracture risk
compared to compliant use. In a study of Belgian
women, also treated with bisphosphonates, each de-
crease of MPR with 1 % was correlated to an increase
in fracture risk by 0.4 % [1].
3. Discussion
This study reviewed articles reporting on several
outcome measures of adherence with medical treat-
ments (except for calcium and vitamin D only).
There are different strengths and drawbacks with
different methods to assess these different outcomes.
Database derived approaches to adherence results in
a limited choice of outcomes, but can on the other
hand provide a higher degree of comparability and
enables studies of larger populations. The availability
of databases that register drug use is naturally a
prerequisite for database derived adherence esti-
mates. These kinds of databases are more widely
available than is suggested by the publications iden-
tified. E.g. Sweden, Denmark, Finland, Italy and
Spain all have databases enabling this kind of re-
search. The countries for which data are included in this
literature review are shown in Fig. 20. Furthermore, a
number of publications on adherence to pharmacological
therapies for osteoporosis in clinical practice have recent-
ly been published from Scandinavia [26–31]. These were
not captured by the literature review, due to the date
limits imposed on the search. Thus, data from Eastern
and North Europe were scarce using the defined inclusion
criteria. In general, more information was available from
the larger countries, e.g. data were abstracted from all
EU5 countries.
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Adherence, as measured by persistence and compli-
ance, was suboptimal in all studies included in this
literature review. Of major importance is that it is also
correlated with a decreased clinical effect. Non-
persistence is associated with side effects and other
factors that could be modified in clinical practice
through education, information as well as in research
aiming for refined drug tolerability. Also, the frequency
of dosing should be kept in mind when aiming for
improved outcomes through increased adherence.
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3. Epidemiology of osteoporosis
Summary
The objective of this chapter is to describe the epidemiology
of osteoporosis and its consequences in the countries of the
European Union in 2010. The information presented here
forms the basis for the estimation of burden of osteoporosis
presented in Chapter 4.
The key messages of this chapter are:
In 2010, it is estimated that 22 million women and 5.5
million men in the EU had osteoporosis using the diagnostic
criterion of the WHO.
Incidence rates of hip fractures were available for most, but
not all, countries of the EU whereas information on country-
specific incidence rates of forearm, clinical vertebral fractures
and other osteoporotic fractures was scarce.
The number of new fractures in 2010 in the EU was estimated
at 3.5 million, comprising approximately 620,000 hip frac-
tures, 520,000 vertebral fractures, 560,000 forearm fractures
and 1,800,000 other fractures (i.e. pelvis, rib, humerus, tibia,
fibula, clavicle, scapula, sternum, and other femoral fractures).
Two thirds of all incident fractures occurred in women.
Among people aged 50 years or more who were still alive in
2010, 3.3 million individuals had sustained a hip fracture
(prevalence of prior hip fracture). The corresponding num-
ber of men and women with prior clinical vertebral frac-
tures was estimated at 3.5 million men and women.
In 2010, the number of deaths causally related to fractures
was estimated at 43,000. Approximately 50 % of fracture
related deaths in women were due to hip fractures, 28 % to
clinical vertebral and 22 % to other fractures. Corresponding
proportions for men were 47 %, 39 % and 14 %, respectively.
3.1 Epidemiology of osteoporosis and fracture
The primary objective of this chapter is to map the epidemi-
ology of osteoporosis and its consequences in the 27 member
countries of the European Union—Austria, Belgium, Bul-
garia, Cyprus, Czech Republic, Denmark, Estonia, Finland,
France, Germany, Greece, Hungary, Ireland, Italy, Latvia,
Lithuania, Luxembourg, Malta, Netherlands, Poland, Portu-
gal, Romania, Slovakia, Slovenia, Spain, Sweden, and the
UK—collectively referred to as EU27. The information pro-
vided in this chapter forms the basis for estimating the
burden of osteoporosis, presented in Chapter 4.
3.2 Population at risk
Osteoporosis is a disease most common in the elderly pop-
ulation. Very few fragility fractures occur before the age of
50 years, and the incidence of these fractures increases
progressively with age after 50 years. For the purpose of
this report, we consider the populations at risk to include
men and women from the age of 50 years. The population at
risk in the EU for 2010 is shown by country in Fig. 21.
Collectively, there were 183 million persons aged 50 years
and above in the EU. Germany had the most (33 million)
and Malta the least (152,000) inhabitants at risk in 2010 [1].
Of the population aged above 50 years in the EU27, 77 %
were below 75 years. Out of the total population above
50 years in the European Union, 54 % were women and
46 % were men. The total population in the EU27 stratified
by five-year age intervals is shown in Fig. 22. Going for-
ward, the large middle-aged population combined with a
comparatively small young population is likely to result in
a high absolute number of elderly individuals and an in-
creasing proportion of elderly to middle-aged individuals.
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Fig. 22 Population in EU (in thousands) in 5-year age groups, 2010 [1]
Fig. 21 Population at risk: men and women over the age of 50 in
respective country in thousands, 2010 [1]
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3.3 Prevalence of osteoporosis
Osteoporosis is diagnosed using dual-energy X-ray absorptiom-
etry (DXA), which measures bone mineral density (BMD).
BMD can be measured at various sites, but the diagnostic
reference site is the femoral neck using the NHANES III refer-
ence data [2–4]. According to the criterion set by aWHO Study
Group, osteoporosis is diagnosed when the BMD at the femoral
neck is 2.5 standard deviations or more below the average BMD
of the young white female population [2–4] (see Chapter 1).
Accurate estimates of the prevalence of osteoporosis
require country specific data on the distribution of femoral
neck BMD. As outlined in Chapter 1, large population-
based reference data are lacking in the EU27 countries.
For the purposes of this report, it is assumed that the mean
femoral neck BMD is similar across countries at the age of
50 years as is the rate of bone loss at the femoral neck with
age. The same assumptions have been used elsewhere [5–7].
On this basis, the prevalence of osteoporosis can be
calculated from the age- and sex-specific prevalence of
osteoporosis in the NHANES III study as given for Sweden
in Chapter 1. These prevalence estimates are then applied to
the population demography in each EU country. Approxi-
mately 5,500,000 osteoporotic men and 22,100,000 osteo-
porotic women resided in the EU27 in 2010, i.e. there were
four times as many women with osteoporosis as there were
men. Of all countries in the EU27, Germany was estimated
to have the highest number of individuals with osteoporosis
with approximately 1 million osteoporotic men and 4 mil-
lion osteoporotic women. Overall the prevalence of osteo-
porosis was 6.6 % and 22.1 % in men and women aged
50 years or more and 5.5 % in the general population (Table
23). In men aged 50 years or more, the prevalence of
osteoporosis varied from 5.7 % in Slovakia to 6.9 % in
Greece, Italy and Sweden. The corresponding data for wom-
en were 19.3 % for Bulgaria and 23.4 % for Italy (Table 24).
The prevalence of osteoporosis increases progressively
with age, though the absolute number of individuals with
Table 23 Estimated number of men and women with osteoporosis (defined as a T-score of −2.5 SD or less at the femoral neck), prevalence in men
and in women over 50 years, and prevalence in the total population, 2010
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osteoporosis increases less markedly (Table 24). When
stratifying the population between 50 and 80 years in five-
year age groups, the highest number of women with osteo-
porosis (approximately 3,900,000) was observed in the
75–79 year age group. However, for men the highest esti-
mated number of individuals with osteoporosis was found in
60–64 year age group (approximately 800,000). The num-
ber of men and women with osteoporosis and prevalence of
osteoporosis stratified by five-year age groups are given in
Table 24.
3.4 Incidence of fractures
The clinical significance of osteoporosis lies in the fractures
that occur as a consequence of increased bone fragility. Infor-
mation on the incidence of fragility fractures varies between
the countries of the EU27. In general, reports on hip fracture
incidence are more commonly available than fractures at other
sites. This arises because a very high proportion of hip frac-
tures are treated in hospitals on an inpatient basis, so that the
data are captured through hospital statistics. Other fractures
are to a significant extent treated in an outpatient setting and
are thus more difficult to monitor in a community. The frac-
tures of interest in this section are fractures of the hip, spine
and forearm as well as fractures at other sites characteristic of
osteoporosis, termed ‘other fractures’.
Incidences of fractures were obtained from a literature
review in which Medline was searched for articles using the
keywords “Country” and “Fracture” and “Incidence”. Titles
and abstracts identified by the search were screened and
potentially relevant articles retrieved in full text. Furthermore,
all abstracts presented at the IOF and ECCEO conferences
since 2000 were screened for additional data. For the EU5, the
incidence used in Strom et al. was used, except for Italian data
on hip fracture incidence [8], which were updated consistent
with a revision of the FRAX model.
For hip fractures, where available, data used to populate
FRAX models were chosen since these provide most re-
cent data and have been evaluated as high quality [9]. For
the remaining countries, national data were preferred over
regional estimates. For the countries where hip fracture
incidence was not available (or only available for the
female population), incidence was imputed from the
nearest country with hip fracture incidence available.
Where the incidence of fractures other than the hip was
not available, the incidence was imputed from the hip
fracture incidence in the relevant country, using the rela-
tionship between hip fracture incidence and incidence of
fracture in other sites in Sweden [10]. This assumes that
the ratios between age and sex specific incidence of hip
fracture and fractures of other sites found in Sweden are
similar in other countries. This assumption, which is also
used in some FRAX models, has been shown to hold true
for the countries where this has been tested [11, 12].
Examples are given in Fig. 23. Age-specific incidence
was linearly interpolated between the age intervals, and
the value shown for each interval was set for the age in the
middle of the interval (e.g., the incidence rate for women
70–74 was used for a 72-year old woman).
3.5 Incidence of hip fracture
In order to compare fracture rates we standardised fracture
rates to the EU population for 2010. The comparison assumes
Table 24 Estimated number of men and women with osteoporosis (defined as a T-score of −2.5 SD or less at the femoral neck) and prevalence in the
population aged over 50 years in the EU27, 2010
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that the age- and sex-specific rates have remained unchanged
between the year of ascertainment and 2010. EU standardized
(2010) hip fracture rates and associated information on the
source of the data for all member countries are shown in Table
25. Where available, country specific age-stratified incidence
rates are provided in the country specific reports published
concurrently with this report.
There was a marked heterogeneity in hip fracture risk
between countries. In women, the lowest annual incidences
were found in Romania and Poland with the highest rates
observed in Denmark and Sweden. There was an approximate-
ly 3-fold range in hip fracture incidence. The heterogeneity in
hip fracture risk is less than that observed on a worldwide basis
(a ten-fold range) but nevertheless substantial. The incidence
of hip fracture in men was approximately half that noted in
women (visualised in Fig. 24). Thus where higher rates were
observed in women, higher rates were found in men and vice
versa. There was a significant correlation between the rates in
men and women (r=0.86; p<0.001).
The differences in fracture rates between men and
women are largely explained by differences in femoral
Table 25 Information available on hip fracture incidence and EU standardised (2010) hip fracture rates (per 100,000 per year)
a Quality: G good; F fair; P poor [9], b Catchment: N national; R regional, c Data not available and incidence from Poland used as a surrogate.,
d Data not available and incidence from Greece used. e Data not available and incidence from Finland used. f Data not available and incidence from
Belgium used. g Data only available for female population, h Mean value of five regions described in three studies, i Abrahamsen, B., personal
communication, 2011; j Kroger, H and Sund R., personal communication, 2011; k Schrembi, A., personal communication, 2011; l Czerwinski, E.
and Lorenc, R., personal communication, 2011.
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neck BMD. Indeed the incidence of hip fracture in men at any
given age is similar to that of women at the same age if both
have the same BMD [32, 33]. The reason for the variation in
hip fracture rates between countries is not known. Many risk
factors for osteoporosis, and in particular for hip fracture have
been identified which include a low body mass index, low
BMD, low calcium intake, reduced sunlight exposure, early
menopause, smoking, high alcohol consumption, low physical
activity levels and migration status. These may have important
effects within communities but do not explain differences in
risk between communities [29]. The factor which is most
closely associated with the variability is socio-economic pros-
perity, in that higher hip fracture rates are observed in those
countries with the higher GDP [34]. This in turn, may be related
to low levels of physical activity or an increased probability of
falling on hard surfaces. This is plausible, but only a hypothesis.
Paradoxically, socioeconomic prosperity may protect against
hip fractures within countries [35]. The contrast between eco-
logical and population risk factors is not uncommon and in the
context of hip fracture, for example, is also noted with calcium
nutrition where countries with higher calcium intakes have the
greater hip fracture risk [36, 37].
3.6 Incidence of vertebral fractures
Vertebral fractures may be defined in several ways. Mor-
phometric vertebral fractures are identified as radiographic
deformities which may be either symptomatic or clinically
silent. Thus, not all morphometric vertebral fractures come
to clinical attention and the proportion that does, varies
between studies and between countries [38–40]. Several
studies indicate that the ratio of clinical to morphometric
fractures is approximately 1 in 5 in women and 2 in 5 in
men [39–41]. Morphometrically diagnosed fractures are
associated with morbidity and increased risk of future
fractures. It should however be noted that they also in-
clude the fractures that come to clinical attention, which
makes the burden attributable to purely sub-clinical frac-
tures difficult to assess. In the context of this report, the
incidence of clinically relevant vertebral fractures was
estimated, since individuals affected by these are most
likely to be identified for treatment. Clinical vertebral
fractures are also more readily linked to cost and Health
Related Quality of Life (HRQoL) consequences. Undoubt-
edly however, this leads to an underestimation of the
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Table 26 Estimated incidence (per 100,000) in the male and female population over 50 years of clinical vertebral fractures adjusted to the
age-distribution in the EU27 in 2010
Note: All incidences (except for Sweden), are estimated using Swedish ratios between hip and vertebral fractures and the country-specific
hip fracture incidence. (Swedish fracture incidences are from Malmö, Sweden [10].)
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burden of vertebral fractures. Data on the incidence of
clinical vertebral fractures, capturing fractures treated in
both inpatient and outpatient settings, are lacking in most
of the countries in the EU, the exceptions being Sweden
and UK. In the UK, the incidence of clinically identified
fractures has been studied within the General Practice
Research Database (GPRD) [40]. The incidence is, how-
ever, very low and it is likely that the majority of fractures
were not coded [42]. Indeed, reported rates of vertebral
fracture vary by more than 10-fold in general practice in
the UK [43]. The ratio of clinical fractures identified in the
GPRD to those identified by morphometry in the UK is
unrealistically low compared with other countries [44],
supporting the view that the GPRD database significantly
under-reported clinical vertebral fracture.
For this reason, vertebral fracture rates were imputed for all
countries except Sweden, where high quality data reporting
the incidences of hip and vertebral fractures that come to
clinical attention were available from Malmö [10]. It was
assumed for each age and sex that the ratio of the incidence
of vertebral fracture to hip fractures in Malmö, Sweden would
be comparable to the ratio of vertebral fracture incidence to
hip fracture incidence in each EU country. The estimated
incidence of clinical vertebral fractures standardised to the
age-distribution in the population above the age of 50 years
in the EU27 is shown in Table 26. The country-specific
variations in clinical vertebral fracture incidence correspond
to that seen for hip fracture incidence due to the method of
imputation. In women, the standardised incidence ranged
from 206 in Poland and Lithuania to 555 per 100,000 in
Denmark whereas in men it ranged from 91 to 374 in UK
and Denmark. The incidence of clinical vertebral fractures in
both men and women above the age of 50 years ranged from
172 in Spain to 471 in Denmark. Further details on the
incidence of clinical vertebral fracture for ages 50–80 years
are presented in the country specific reports published con-
currently with this report.
3.7 Incidence of forearm and other osteoporotic fractures
The forearm (distal forearm, distal radius, wrist) is a
common site of osteoporotic fractures. The incidence of
forearm fractures increases with age, although not as
steeply as that of hip fracture. The majority of forearm
fractures are treated in hospital out-patient departments.
There are reports from EU27 countries on the incidence
of forearm fractures leading to hospitalisation, e.g. from
France [45]. There are also studies published from Slo-
venia [27] and Italy [46] which present the incidence of
forearm fractures treated in inpatient and/or outpatient
care. However, the Slovenian study only reports frac-
tures occurring in women, and the Italian study lacks
age stratification of data within the elderly population.
Forearm fracture incidence presented in a form suitable
for this study was only available for Hungary [20], the
UK [31] and Sweden [10]. For other countries, forearm
fracture incidence was imputed from the hip fracture
incidence in the relevant country, using the relationship
between hip fracture incidence and forearm fracture
incidence in Sweden.
In addition to hip, spine and forearm fractures, fractures
at several other sites are considered to be causally related to
osteoporosis in that their respective incidence increases with
age and they are associated with low BMD (see Chapter 1).
Fractures of the femur, pelvis, humerus, rib, clavicle, scap-
ula and sternum are in this report grouped as “other frac-
tures”. Their incidence is only available in complete form
for Sweden, and therefore incidence is imputed for other
countries using the same method as for vertebral and fore-
arm fractures described above.
3.8 Number of incident fractures
The number of fragility fractures occurring in the EU27 in
2010 was estimated using age- and sex-specific incidence
rates and age- and sex specific population data. The majority
of the fractures sustained (Table 27) were “other fractures”
(approximately 1,800,000) followed by hip (600,000), fore-
arm (600,000) and clinical vertebral fractures (500,000). In-
dividuals 80 years of age or more sustained the majority of hip
fractures whilst most of the forearm fractures were found in
younger age groups. The highest number of vertebral fractures
occurred in individuals between 70 and 75 years of age.
Whilst incidence rates of fractures increased with age, the
increase in the absolute number of fractures levels off in the
older age groups, reflecting a decrease in the population at risk
with age. When stratifying the population between the ages of
50 and 95 years in 5 year age groups, the highest estimated
numbers of women with hip (approximately 110, 000), and
“other” fractures (210,000) were observed in the 85–90 year
age group whereas the highest numbers of vertebral (55,000)
and forearm fractures (70,000) were observed in the 80–84
and 70–74 year age groups, respectively. For men the highest
number of hip (approximately 36,000), vertebral (31,000),
forearm (18,000) and other fractures (113,000) were found
in the 80–84, 70–74, 60–64 and 80–84 year age groups
respectively. Overall, the highest number of fractures was
found in men and women aged 80–84 years.
The number of incident fractures per site and country is
shown in Table 28. Germany had the highest number of
fractures for all fracture types in both men and women—
approximately 725,000 incident fractures in total—
predominately reflecting a large population size and compar-
atively high fracture incidence. Malta and Luxembourg had
the lowest number of fractures for all types—(approximately
3,000 incident fractures in total in each country), reflecting
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small population sizes. The sum of all incident fractures was
estimated at approximately 3,490,000 in the EU in 2010. This
equates to 9,556 new fractures per day (390 per hour).
Almost twice as many fractures occurred in women com-
pared to men. Hip, vertebral, forearm and “other fractures”
accounted for 18 %, 15 %, 16 % and 51 % of all fractures
respectively (Fig. 25).
3.9 Prior fractures
In assessing the burden of osteoporosis, it is important to
consider the number of fractures that occurred in the popu-
lation before the index year, in this case 2010. Fracture at
some sites are associated with morbidity that extends be-
yond 1 year, and estimating the number of prior fractures
permits estimation of long-term suffering as a consequence
of fracture. This is particularly true for hip fracture but also
Table 27 Estimated number of incident fractures stratified by age and fracture type in the EU27, 2010
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Fig. 25 Proportion of incident fractures in 2010 by site (top) and sex
(bottom)
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applies to other fracture sites [39]. In this study, the long
term effects of hip and vertebral fractures are taken into
account, thus the prevalence of prior fractures at these sites
has been estimated.
An additional clinical significance of a prior fracture is
that it is a significant risk factor for a further fracture. A
prior fracture leads to an approximately two-fold increase in
fracture risk [47] and this risk factor is largely independent
of BMD [48–50]. A prior history of a fragility fracture is
one of the major risk factors used in the assessment of
fracture risk and is incorporated into the FRAX algorithms.
As might be expected, the prevalence of a prior fracture
increases with age [51] but the absolute prevalence depends
critically on the construct of the question used. For example,
the frequency of a positive history will differ if fractures are
sought from the age of 40 years or 50 years.
For the purposes of this report, a prior fracture was
defined as a fracture in an individual who was alive during
the index year (i.e. 2010), which had occurred after the age
of 50 years and before 2010. The unit was the individual so
that multiple fractures at the same site in one individual
were only counted as one prior fracture of that site. The
number of prior fractures is not as easily accessible as the
number of incident fractures, and must instead be simulated.
A micro-simulation model, programmed in TreeAge, was
used to simulate the prevalence of prior hip and vertebral
fractures from incidence data. The micro-simulation model
was populated with the hip and clinical vertebral fracture
incidence data described above, normal population mortality
[52, 53], and Swedish relative risks of post-fracture mortal-
ity [54]. Age-specific prevalences of prior hip and prior
clinical vertebral fracture were multiplied by the age-
specific population in each country [1] to derive the number
of prior fractures present in 2010.
The estimated number of individuals with a prior fracture
varied considerably by age and the majority were found in
the elderly (Table 29). The number of individuals with a prior
hip fracture peaked in age group 80–84 and 85–89 for men
and women, respectively. Vertebral fractures were more
common in younger age groups (70–74 for men and 80–84
for women), due to a less steep incidence increase by age
combined with increased mortality after fracture. The
Table 28 Estimated number of incident fractures by type and country, 2010
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proportion of prior fractures that engendered disability in
2010 is unknown but likely depends on fracture site, the time
since fracture and the individual’s age.
The majority of individuals with a prior fracture were
women (4,800,000 women compared to 1,900,000 men)
(Table 29).
The estimated proportion of subjects with prior hip
and vertebral fractures increased monotonically with age
in men and women, from below 1 % in individuals
younger than 60 years to 24.3 % (women) and
14.6 % (men) for hip fractures and 15.0 % (women)
and 12.5 % (men) for vertebral fractures (Table 29) in
individuals older than 95 years. The reason the propor-
tion of subjects with prior fractures increased monoton-
ically with age whereas the absolute number of prior
fractures did not, reflects that the population at risk
(denominator in the calculation of the proportion) de-
creases with age.
The estimated number of men and women with a prior
hip or vertebral fracture is shown in Table 30. The total
number of prior fractures was estimated at approximately
6.8 million in the EU27 in 2010, comprising 3.3 million
men and women with a prior hip fracture and 3.5 million
with a prior clinical vertebral fracture.
Table 29 Number of individuals in the EU27 2010 with a prior hip or clinical vertebral fracture occurring before 2010 stratified by age group
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The estimated proportion of individuals (aged 50 years
or more) with a prior hip fracture in the EU27 in 2010
amounted to 2.4 % in women (ranging from 1.1 % in
Romania to 3.6 % in Sweden) and 1.1 % in men
(ranging from 0.7 % in Ireland, Malta, Netherlands,
Poland, Portugal and Spain to 2.0 % in Sweden). For
clinical vertebral fractures the corresponding estimates
were 2.5 % (ranging from 1.3 % in Bulgaria, Poland
and Romania to 4.1 % in Sweden) and 1.2 % (ranging
from 0.7 % in e.g. Portugal and Lithuania to 2.2 % in
Sweden). The female to male ratio for both hip and
vertebral fractures was approximately 2. The proportion
of individuals with a prior fracture by country is
presented in Table 31.
It is relevant to note that the estimates above relate to a prior
hip or vertebral fracture, which underestimates the prevalence
of any prior fragility fracture. Using a different approach, the
prevalence of a prior fracture has been estimated for Spain,
France, UK, Germany, Italy and Sweden.
Table 32 summarises the data for these countries which
show the prevalence of all prior fractures in 2010 undertak-
en with a more complete assessment compared with the
estimates above. The estimation of prior vertebral + prior
hip fracture appears to capture approximately 30 % of prior
fractures.
3.10 Mortality due to fracture
Independently of fracture status, low bone mineral den-
sity is associated with an increase in mortality [58–61].
Over and above this excess mortality, some specific
fracture sites are associated with increased mortality
[59, 62, 63]. Although the mortality after a fracture
has been reported to be higher for men compared to
women [62], the mortality hazard in the general popu-
lation is higher in men than in women. Thus, the
difference in mortality between men and women is less
marked when relating the mortality to that of the gen-
eral population of the same sex [63–66]. Several studies
have shown that mortality is highest in the immediate
fracture period and then decreases with time. However,
it remains higher than that of the general population
[62, 67–70]. The pattern of mortality after fracture has
been well characterised in Sweden [65, 69].
Table 30 Estimated number of men and women aged above 50 years with a prior hip or vertebral fracture by country, 2010
Page 61 of 115, 136Arch Osteoporos (2013) 8:136
In order to compute the mortality after fracture, we
used the age- and country specific mortality rates for
men and for women [52, 53]. To these data, we ap-
plied the relative risks of death documented for Swe-
den to estimate the country-specific mortality rates
after a fracture. The calculation assumes that the
relative risk of death after fracture is similar to that
of Sweden in all EU countries. The adequacy of this
assumption is unknown but it is likely that death rates
are higher in those countries with poorer health care
facilities. Thus the estimates provided are likely to be
conservative.
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Table 31 Estimated proportion of men and women above 50 years with a prior hip or vertebral fracture by country, 2010
Table 32 Estimates of the prevalence of prior hip and clinical vertebral fracture (the present study) and the prevalence of all fragility fractures
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Age differentiated mortality in the first year after a ver-
tebral or hip fracture relative to the age- specific mortality of
the Swedish population is shown in Table 33 [69]. The
relative risk of death decreases with age, even though the
absolute mortality increases. We assumed no excess mortal-
ity after a fracture of the forearm, in accordance with the
published literature [62, 67, 69, 71]. For other fractures, a
relative excess mortality of 1.22 was assumed for all ages
[12, 72, 73].
The increase in mortality seen after a fracture cannot be
entirely attributed to the incident fracture itself because of
the high levels of co-morbidity, particularly in patients
with hip and vertebral fracture [59, 74, 75]. In health
economic studies of osteoporosis, it is the excess mortality
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Table 33 Relative risk of death in the first year after fracture [69]
Table 34 Number of deaths after fracture and deaths directly attributed to fractures within the first year, after adjusting for co-morbidities, 2010
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that would be avoided in the absence of a fracture that is
important to consider. A common assumption [76–79] is
that 30 % of the excess mortality is directly caused by the
fracture, which is supported by studies by Parker and
Anand [80], Tosteson et al. [81] and Kanis et al. [82,
83]. In this report, it was assumed that 30 % of the excess
mortality during the first year was attributable to the
fracture itself and that excess mortality related to the
fracture was only present during the first year.
3.11 Deaths due to fracture
When combining the country- and age-specific estimates
of incidence and post-fracture mortality, the total number
of deaths occurring in the first year after fracture was
estimated at 143,000. After adjusting for co-morbidities,
the numbers of deaths in 2010 during the first year after
fracture attributable only to the fracture were estimated at
approximately 20,100 and 22,700 in men and women,
respectively. Most deaths occurred in Germany, followed
by the UK, whilst countries with small populations such as
Malta and Luxembourg had the lowest number of deaths.
The number of deaths after fracture and deaths causally
related to fractures in the countries of the European Union
are shown in Table 34.
In total in the EU27, hip, vertebral and other frac-
tures were estimated to result in approximately 11,000,
6,000 and 5,000 deaths in women, directly attributable
to fracture. The corresponding numbers for men were
estimated at approximately 9,000, 8,000 and 3,000
deaths for hip, vertebral and other fractures, respectively
(Table 35). Most notably, vertebral fractures caused
somewhat more deaths in men than in women during
the first year (8,000 in men and 6,000 in women),
although approximately 75 % more fractures occurred
in women than men (Table 28). This is due to a higher
relative mortality (Table 33) as well as a higher general
mortality at higher ages in men. The majority of frac-
ture related deaths occurred in hip fracture patients.
Among men and women who experienced premature
mortality due to a fracture, 47 % and 50 % respectively
were attributable to hip fracture (Fig. 26).
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Table 35 Number of deaths in 2010 directly attributable to fractures within the first year, after adjusting for co-morbidities in women and men aged
50+ years by fracture site
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The number of deaths directly attributable to fracture
in the EU27 in 2010 was estimated at 24 per 100,000
people at risk (aged 50 years or more) and ranged by a
factor of approximately 3-fold in both women (from 14
in Netherlands to 43 in Denmark) and men (from 16 in
Netherlands to 45 in Denmark) (Table 36). The inter-
country variation predominately reflects differences in
fracture incidence.
Similar to the estimated number of fractures, the number
of deaths attributable to fracture decreased in higher age
groups in both men and women (Table 37). The decrease
is a result of fewer people at risk with age (Table 27)
combined with decreasing relative risks of mortality after
hip and vertebral fractures (Table 33). However, in both men
and women, almost half of the deaths were incurred in ages
80–89 years.
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Table 36 Incidence (per 100,000 inhabitants aged 50+ years) of deaths directly attributable to fractures within the first year, after adjusting for co-
morbidities by fracture site in 2010
Men
Women
47%
39%
14%
Hip
Spine
Other
50%
28%
22%
Fig. 26 Proportion of deaths due to fracture by site in men (top) and
women (bottom)
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4. Burden of fractures
Summary
The objective of this chapter is to estimate the burden of osteo-
porosis in terms of QALYs lost and total costs in the countries of
the European Union in 2010. Fracture burden is also projected
to year 2025 based on expected demographic changes.
Key messages of this chapter are:
The cost of osteoporosis, including pharmacological interven-
tion in the EU in 2010 was estimated at €37 billion. Costs of
treating incident fractures represented 66 % of this cost, phar-
macological prevention 5 % and long-term fracture care 29 %.
Excluding cost of pharmacological prevention, hip fractures
represented 54 % of the costs, “other fractures” represented
39 %, and vertebral and forearm fractures represented 5 %
and 1 %, respectively.
The estimated number of life-years lost in the EU due to
incident fractures was approximately 26,300 in 2010.
The total health burden, measured in terms of lost QALYs,
was estimated at 1,180,000 QALYs for the EU. Twice as
many QALYs were lost in women compared to men.
The majority of the QALYs lost were a consequence of prior
fractures.
Assigning a QALY the value of 2xGDP, the total value of
QALYs lost in 2010 was estimated at €60.4 billion.
Due to changes in population demography the number of men
and women with osteoporosis, using the diagnostic criterion
of the WHO, will rise from 27.5 million in 2010 to 33.9 million
in 2025, corresponding to an increase of 23 %.
The annual numberof fractures will rise from 3.5million in 2010
to 4.5 million in 2025, corresponding to an increase of 28 %.
The number of QALYs lost annually due to fractures will
increase from 1.2 million in 2010 to 1.4 million in 2025,
corresponding to an increase of 20 %.
The total cost including values of QALYs lost (valued at 2×
GDP per capita) in the EU27 will rise from €98 billion in 2010
to €121 billion in 2025, corresponding to an increase of 22 %.
4.1 Introduction
Disease burden is the impact of a health problem measured by
mortality, morbidity, financial cost or other measures. In the
case of osteoporosis, burden can inter alia be quantified as the
number of fractures, the number of people suffering the con-
sequences of a fracture, or life years lost due to fracture. Cost
of illness is a measure of burden quantified in monetary terms.
Costs are generally classified as direct, indirect and intangible.
Direct costs constitute healthcare and non-healthcare costs,
indirect costs arise from productivity losses, and intangible
costs constitute the monetary value of reduced health [1, 2].
Cost of illness studies provide no direct guidance on how
resources should be allocated, but may provide relevant
information concerning the consequences of a disease that
may inform policy. Such studies may aid decisions
concerning societal resource allocation for research, devel-
opment, and funding of new treatments. Results from cost of
illness studies can also be utilised to assess the long term
consequences and value of medical progress.
The main objective of this chapter is to estimate the
current cost of osteoporosis in the countries of the European
Union and to estimate the projected cost of osteoporosis in
the European Union up to 2025.
4.2 Methods and materials
A cost of illness study can take a healthcare payer perspec-
tive (includes all costs carried by the health care system) or a
societal perspective (includes all cost carried by society).
The present study included costs from a societal perspective
as far as possible and the costs of osteoporosis were esti-
mated from the cost consequences of incident and prior
fractures, costs associated with pharmacological fracture
prevention, and a monetary value of QALYs lost. The cost
of osteoporosis is presented with and without intangible
costs (i.e., the monetary value of QALYs lost).
Costs of fracture-related productivity losses were not in-
cluded in the study given that they are only incurred in patients
below the retirement age—median age 60 years in
Europe—and have previously been estimated to be limited
in osteoporosis. For example, productivity losses were esti-
mated to account for less than 5 % of the cost of osteoporosis
in Australia [3], 2.8% of the cost of osteoporosis in Austria [4]
and less than 1 % of hip fracture cost in Sweden [5]. Omitting
costs of productivity loss underestimates the economic burden
of fractures. This is especially true for fractures with a higher
incidence at younger ages such as forearm fractures.
A model previously used to estimate the cost of osteopo-
rosis in Sweden and the EU5 [6, 7] was adapted to include the
countries in the present study. A literature search was
performed to identify the best available health utility, epide-
miological, and economic data with which to populate the
model. The epidemiological data used in the model are de-
scribed in Chapter 3.
The three most common sites of fragility fracture (hip,
vertebral and forearm) were included in the model as well as
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a combination of other fragility fractures (pelvis, rib, humerus,
tibia, fibula, clavicle, scapula, sternum, and lower femur).
Once growth has ceased, skeletal mass is relatively con-
stant until the age of 50 years [5], so that the prevalence of
osteoporosis—as defined by the WHO diagnostic
criterion—and the risk of fractures are low below the age of
50 years [5, 8, 9]. Given the low number of fragility fractures
in patients under 50 years and the dearth of cost and health
utility implications of fractures in this population, the model
was run on a population aged 50 years or above. Whilst it is
difficult to assess the impact of the restriction based on the
available data, it is likely to be small given the low risk of
fragility fractures under the age of 50 years.
4.2.1 Model design
The model employs a prevalence-based bottom-up approach
[10] that uses the number of cases within a defined period of
time multiplied by the corresponding disease-related conse-
quences. Fractures often lead to increased costs and morbid-
ity for several years after the fracture occurs. The
consequences related to fracture can therefore be divided
into an acute or incident phase and a long-term disability
phase. In the acute phase (in this report defined as the first
year after fracture), costs are higher and health effects worse
than in the following long term phase (defined as the period
beyond the first year after fracture). Therefore, the relevant
fracture related costs and health effects were captured within
a defined time period for both incident fractures (i.e., frac-
tures that occur within the year of analysis) and prior frac-
tures (i.e., fractures that occurred in previous years but still
have an impact on costs and quality of life during the study
period). The same method was applied by Ström et al.,
reporting the economic burden of osteoporosis estimation
in the EU5 and Sweden [7].
In short, the calculation of the costs and QALYs lost due
to osteoporosis in 2010 was performed in the following
way: the number of acute fractures was estimated from
fracture incidence and population data for each country
(described in Chapter 3). Subsequently, country-specific
costs and generic health utility multipliers (described below)
were assigned to the number of fractures to derive the cost
and health utility implications for acute fractures. Given that
1 year costs and health utility implications were applied to
all fractures in 2010, the resulting estimates can be
interpreted as the one-year burden of incident fractures in
2010. The number of prior fractures in people above the age
of 50 years was simulated under the assumption of constant
population size and age- and sex distribution, fracture inci-
dence, general population mortality and excess mortality
after fractures. Please see Chapter 3 for further details on
number of incident and prior fractures. Subsequently, country-
specific costs and generic health utility multipliers (described
below) were assigned to the number of prior fractures to
derive the cost and health utility implications of those
fractures. Further details on the method for calculating the
burden of fractures can be found in Ström et al. [7] and
Borgström et al. [6].
4.2.2 Cost of fracture and imputations methods
First-year costs after fracture were obtained from a literature
review where Medline was searched for articles using the
keywords “[Country]” and “Fracture” and “Cost”. Titles and
abstracts identified by the search were screened and poten-
tially relevant articles retrieved in full text. Furthermore, all
abstracts presented at the IOF and ECCEO conferences
since 2000 were screened for additional data. Where costs
of fractures were not available, those were imputed as de-
scribed below. Table 38 provides a summary of references
and imputation methods by fracture type and country.
For hip fractures, cost estimates were available for Belgium
[11], Czech Republic [12], Denmark [13, 14], Finland [15],
Germany, Italy [16], the Netherlands [17], Slovenia [18], Swe-
den [19] and the UK, [20, 21]. Where only hospital costs of hip
fracture were found (Austria [22], Czech Republic [23], Ireland
[24], and Portugal [25]), the ratio between hospital cost and the
total direct costs for hip fractures observed in the Swedish
KOFOR study was used to obtain estimates of the first-year
cost. For countries where fracture costs were not found, the costs
were imputed from the nearest country available by adjusting for
differences in healthcare price levels between the relevant coun-
tries [26]. Following the completion of this report, we were
forwarded data on fracture costs from Slovakia [27]. These are
used as a sensitivity analysis in the country specific report
published in the same issue of Archives in Osteoporosis
For vertebral fractures, studies reporting on costs of
treating fractures in both inpatient and outpatient settings
were available for Denmark, Germany [28], Slovenia [18],
Sweden and the UK [20]. For countries where only
hospitalised clinical fractures costs were found, as for coun-
tries without cost estimates, the costs were derived via mor-
bidity equivalents as estimated by Kanis et al. [29].
Morbidity equivalents can roughly be described as the mor-
bidity a fracture type confers compared to that of a hip
fracture, and costs were assumed to follow the same pattern.
This assumption has been shown to be appropriate, at least in
a US setting [30].
For forearm fractures, inpatient and outpatient cost estimates
were available for Denmark [13], Slovenia [18], Sweden [19]
and the UK [21]. For countries where forearm fractures costs
were not found, costs were derived via morbidity equiv-
alents as described for vertebral fractures above.
When calculating the Swedish cost of fractures grouped as
“other fractures” (pelvis, rib, humerus, tibia, fibula, clavicle,
scapula, sternum, and lower femur), it was assumed that lower
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leg and pelvic fractures were equivalent to hip fractures;
humerus fractures were assumed to be equivalent to vertebral
fractures; and fractures of the rib, clavicle, scapula, and ster-
num were assumed to be equivalent to forearm fractures [19].
Costs were then adjusted to represent the age distribution of
these fractures. For other countries, the costs of “other frac-
tures” were calculated as a share of the first-year hip fracture
costs by assuming the same ratio of first-year hip fracture costs
and “other fracture” costs observed in Sweden. Swedish costs
were stratified by age, and therefore the imputed costs of other
fractures also differed by age group.
Acute hip fracture costs in Europe ranged from approxi-
mately €2,000 in Bulgaria (estimated from Slovenian cost
using PPP) to about €25,000 in Denmark. As a consequence
of imputation, Bulgaria also had the lowest costs for vertebral
fractures (€404), forearm (€112) and other fractures (€929).
The lowest cost of hip fracture for a country with an original
reference was Slovenia (€5,306). The highest costs for verte-
bral and forearm fractures were found in Sweden at €11,413
and €2,401 respectively whereas the highest costs for “other
fractures” were found in Denmark (€12,749). Where applica-
ble, costs were inflated to 2010 year prices using the consumer
price index (CPI) [32]. First year fracture costs for all fracture
types are shown in Table 39.
There are currently no published estimates of long-term
fracture costs based on empirical patient samples. For the pur-
poses of this report, we conservatively assumed that fractures
other than those at the hip did not incur any long-term costs. Hip
fracture costs in the second and following years after the event
are usually based on the proportion of patients that become
institutionalised for the long-term [33, 34]. With increasing
age, an increasing proportion of patients transition from inde-
pendent living to long-term care 1 year after fracture [35].
Patients who at the time of fracture already resided in long-
Table 38 Cost of fracture and imputation methods
= country specific data
= no country specific data
aImputed fromSlovenian data by adjusting for differences in health care price levels, bImputed from Italian data by adjusting for differences in health care
price levels, cImputed from Finnish data by adjusting for differences in health care price levels, dImputed from the UK data by adjusting for differences in
health care price levels, eImputed from Belgian data by adjusting for differences in health care price levels, fImputed from Czech Republic data by
adjusting for differences in health care price levels, gImputed from hip fracture costs via morbidity equivalents as estimated by Kanis et al. [29]
Page 71 of 115, 136Arch Osteoporos (2013) 8:136
term care were assumed not to have any additional long-term
fracture related costs and the rates were down-adjusted accord-
ingly.Moreover, the proportion admitted to long-termcare 1year
after fracture was also down-adjusted to account for the risk of
being admitted due to causes not related to the hip fracture itself.
The annual risk of being institutionalised in long-term care in the
general population in Sweden is approximately 0.1 %, 0.5 %,
and 2 % for 65-, 75- and 85-year old individuals, respectively
[36]. When individuals transitioned from independent living to
long-term care, it was assumed that they remained dependent
until death. Data on the proportion of patients who transition to
nursing home after a hip fracture and on the probability of
transition to nursing homes in the general population are scarce,
and Swedish data were therefore used for all countries. This is a
reasonable proxy for countries in Northern Europe, e.g., Scot-
land [37], but may be an overestimate for countries in other parts
of Europe, where long-term care to a larger extent is provided by
informal care givers (e.g., a spouse or child). Informal care is
however also associated with societal costs such as productivity
losses, lost leisure time, and out-of-pocket expenses. In this
report, we assumed that the costs of long-term care of hip
fractures are similar irrespective of whether they are incurred
by informal or formal care. Swedish risks of transitioning to
nursing homes are thus used as a proxy for the risk of being
disabled in the long-term after a hip fracture.
The annual hip fracture cost beyond the first year after
fracture was obtained by multiplying the yearly cost of residing
in a nursing home with the simulated number of prior fractures
transferring to nursing homes adjusted for proportions described
above. For countries where yearly cost of residing in a nursing
home was not found, costs were imputed from the nearest
country available by adjusting for differences in healthcare price
levels between the relevant countries [36]. Table 40 lists the
costs, references and imputation methods by country.
4.2.3 Costs of pharmacological prevention of fracture
In addition to the first and subsequent year costs of fracture
detailed above, patients with established osteoporosis may be
prescribed bone protective treatment. The number of pre-
scribed daily doses per country (2010) for each relevant phar-
maceutical intervention (alendronate, risedronate, etidronate,
ibandronate, raloxifene, zoledronic acid, strontium ranelate,
teriparatide and PTH) were obtained from IMS Health and
multiplied by the unit costs for respective drug in each country
[52]. In addition to costs for pharmaceuticals, patients on
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Table 39 First year cost of hip, vertebral, forearm and other fractures (€, 2010). References are shown in Table 40
aCost ranged with age from €12,870 to €19,667,bCost ranged with age from €2,048 to €14,219,
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therapy were assumed to incur costs for an annual physician
visit and a BMD measurement every second year. The cost of
DXAwas taken from two IOF audits [53] [54]. Furthermore,
there may also be other costs related to pharmacological treat-
ment of osteoporosis such as costs for medication to treat side
effects. However, those were not included in the analysis.
Costs for first and second line treatment per year (weighted
on price and market share in each country) are presented in
Table 41 together with unit costs for BMD measurement and
physician visits.
4.2.4 Health utility and QALY implications of fracture
The health burden of osteoporosis can be measured in terms
QALYs lost. The QALY is a multi-dimensional outcome
measure frequently employed in health economic analysis that
incorporates both the quality (health related) and quantity
(length) of life. QALYs are derived by multiplying the dura-
tion of life (years) with a health utility between 0 (death) and 1
(perfect health) [96]. For example, a person who lives for
5 years with a health utility of 0.8 would accrue four QALYs
during those 5 years.
Health utility can be measured using the EQ-5D instrument,
which rates health status grouped by physical, social and
mental aspects in five dimensions (mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression) with a
three level answer for each dimension, resulting in a total of
243 (35) possible EQ-5D health states. Each EQ-5D health
state may be converted to health utility by applying a formula
that attaches weights to each of the levels in each dimension.
This formula is based on the valuations of the health states
from general population samples. Whilst a pan-Europe EQ-5D
has been developed using a visual analogue scale, preference
based valuation sets are preferable in economic studies and
these have only been derived for the UK, Denmark, Germany,
the Netherlands, Spain and Sweden, with the UK valuation set
having been deemed the most robust [97]. Consequently, the
preference based UK valuation set and normal population
health utility were used for all countries.
Fracture can result in loss of health in all EQ-5D dimen-
sions. Effects on the physical dimensions include factors such
as increased pain, loss of mobility and capability of self-care.
The perception of social role and impact on activities can also
be affected in the social dimension. There is also a mental
dimension which can be affected by, for example, depression,
anxiety or loss of self-esteem [98]. Consequently, fractures
result in reduced health utility and reductions differ substan-
tially among the fracture types, and likely between countries
[99]. Hip and vertebral fractures have the greatest impact on
health utility whereas forearm fractures are associated with
less health utility loss over a shorter period of time; most
patients return to their pre-fracture utility after 12 months
[99]. The loss of health utility is greatest for all fractures in
the first year and decreases in subsequent years [98].
The health utility in the first year after hip, clinical vertebral
and forearm fracture relative to the age-specific health utility
in the normal population has been estimated at 0.70, 0.59 and
0.96, respectively [100]. Other fractures were assigned 85 %
of the age specific health utility. Age-specific health utilities
after fracture were derived by multiplying the health utility of
the general population of the relevant age by the health utility
multipliers for fracture. For example, a 75 year old man
(average health utility of in men aged 75 years is 0.72) who
sustains a hip fracture has a health utility loss of 0.216
(=0.72×(1–0.70)) in the first year after fracture, resulting in
a loss of 0.216 QALYs (=1×0.216).
The health effects of fractures may extend beyond the first
year after fracture. Hip and vertebral fractures have been shown
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Table 40 Annual nursing home costs (€, 2010)
a
Approximated by adjusting the Bulgarian cost for health adjusted price levels,
b
Approximated by adjusting the Finnish cost for health adjusted
price levels,
c
Approximated by adjusting the UK cost for health adjusted price levels,
d
Average of four nursing home facilities,
e
Approximated by
adjusting Belgian cost for health adjusted price levels,
f
Approximated by adjusting Italian cost for health adjusted price levels,
g
Approximated by
adjusting the German cost for health adjusted price levels,
h
Approximated by adjusting the Spanish cost for health adjusted price levels
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to have long-lasting effects on health and were modelled to
reduce health utility to 80 % [100] and 94 % [101] of that of
non-fractured individuals beyond the first year after fracture.
Conservatively, neither forearm, nor “other fractures” were
modelled to have long-term effects on health utility.
Hip and vertebral fractures are also associated with in-
creased mortality and studies suggest that approximately
30 % of the excess mortality observed after fracture may be
directly attributable to the fracture event [102–104]. “Other
fractures” have also been associated with increased mortality
directly attributable to the fracture and were modelled to in-
crease risk of mortality by 12 % [105]. Because deaths attrib-
utable to fracture may not occur immediately after the fracture,
they do not result in one whole life year lost in the index year
(2010). Based on data from the Swedish Inpatient andCause of
Death Registries presented in Borgström et al. [6], we
modelled that deaths attributable to fracture occurred 140 days
after fracture, resulting in approximately 2/3 life years lost in
2010. QALYs lost to due post-fracture mortality are fewer than
life years lost due to post-fracture mortality reflecting that
individuals with fracture are not in perfect health. Life years
lost resulting from deaths attributable to fractures occurring
prior to 2010 were not incorporated into the model.
Similar to the methodology used to estimate costs described
above, the estimate of total QALYs lost comprisedQALYs lost
due to incident fracture (i.e., QALYs lost due to fractures in the
index year (2010)) and QALYs lost due to prior fracture (i.e.
QALYs lost due fractures incurred prior to the index year, but
which resulted in health utility loss in 2010). This prevalence
model only account for QALYs lost due to death in the incident
year, and thus substantially underestimates QALYs lost com-
pared to an incidence model. The latter should account for all
life years lost in the case of fracture compared to no fracture.
4.2.5 Societal value of QALYs
The value of a QALY may differ between and within coun-
tries due to a number of factors including degree of pros-
perity, cultural attitudes and the opportunity costs of
resources devoted to obtain a marginal QALY [106].
There are two methods to elicit the value of a QALY: stated
preferences and implicit valuation. In the stated preference
approach, people are directly asked for their preferences
whereas in implicit valuation preferences are elicited from
actual choices, e.g., the premiumwage a job with an increased
risk of mortality or morbidity commands [106].
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Table 41 Unit costs for treatment and management in (€, 2010)
a Approximated by adjusting Polish cost for health adjusted price levels [26] b Approximated by adjusting Romanian cost for health adjusted price
levels [26], c Approximated by adjusting Italian cost for health adjusted price levels [26], d Approximated by adjusting Polish cost for health
adjusted price levels [26].
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Valuing health as a function of GDP allows for variations
in ability to pay for health between countries and the WHO
Commission on Macroeconomics and Health has suggested
that one averted DALY can be valued at three times GDP per
capita [107]. This criterion has been used in health econom-
ics studies. For example, Murray et al. [108] classified treat-
ments based on the cost per healthy life year gained as very
cost-effective at≤1× GDP per capita and as cost-effective
at≤3×GDP per capita. Whereas DALYs and QALYs are
conceptually similar, they are based on different methodolo-
gies and are therefore not directly comparable [109]. How-
ever, a comparison of available estimates for different
disease areas for the two outcome measures does not suggest
a substantial difference in terms of GDP per capita valuation
[106–108]. Consequently, we followed the approach of
Borgström et al. [6] and Strom et al. [7] and set the value
of a QALY at 2×GDP per capita.
4.3 Results
4.3.1 Costs of osteoporosis excluding values of QALYs lost
Several factors affect the cost of osteoporosis excluding the
value of QALYs lost in a country, including age specific
fracture risks, population size, age and sex distribution,
fracture-related costs and the cost of pharmacological inter-
vention. Three cost components are included in the model:
cost first year after fracture, cost subsequent years after
fracture, and cost of pharmacological fracture prevention
including administration and monitoring costs.
The cost of osteoporosis, excluding value of QALYs lost
in the EU27, amounted to €37.4 billion in 2010. First year,
subsequent year, and pharmacological costs accounted for
66 %, 29 % and 6 % of the costs, respectively. Whilst the
proportion of costs for pharmacological prevention to total
costs was low on average, some inter-country variation was
observed: the lowest proportion of costs attributable to
pharmacological intervention was observed in Sweden
(2 %) and the highest costs in Cyprus (22 %). The high cost
share in Cyprus might be explained by Cyprus having the
highest number of doses of anti-osteoporosis drugs sold per
person. In addition, the highest price of alendronate in the
EU27 was observed in Cyprus. The cost of osteoporosis
stratified by the three cost categories for each EU27 country
in 2010 is presented in Table 42 below.
Hip fractures were estimated to account for 54 % of
the total costs, other fractures 39 %, vertebral fractures
5 %, and forearm fractures 2 % (Fig. 27). The estimate
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Table 42 Cost of osteoporosis (excluding value of QALYs lost) in EU27 in 2010 (€ million, 2010)
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of 39 % for other fractures may be perceived as a high
figure given that most health economic evaluations of
fracture prevention mainly focus on hip and vertebral
fractures [14, 110–112]. However, such studies usually
evaluate treatment in elderly women where the risks of
hip and vertebral fractures are greater than that of the
risk of “other fractures”. By contrast, the current study
captured all fractures in all patients aged 50 years or
more. Note that costs attributable to fractures in Fig. 27
do not incorporate costs of pharmaceutical intervention.
The highest costs were incurred by fractures occurring in
individuals aged 80–89 years. Hip and “other” fracture costs
peaked in this age group, while costs for forearm and ver-
tebral fractures peaked in individuals aged 70–79 years.
Fracture costs by site and age are given in Table 43.
The total costs for osteoporosis (excluding the value of
QALYs lost) were compared to total healthcare spending in
the respective country (Table 44). Healthcare spending var-
ied markedly between countries, ranging from €500 million
in Malta to €281 billion in Germany. The total spend on
healthcare in the European Union amounted to €1,260 bil-
lion, with the cost of osteoporotic fractures representing
3 %. The share varied across countries, and the extremes
were represented by Cyprus where fracture burden repre-
sented approximately 5 % of the total healthcare spending
and Luxembourg where the corresponding number was
approximately 1 %. It should be noted; however, that not
all fracture related costs come from the healthcare budgets
of the countries (e.g., long-term care).
The cost of osteoporosis per capita, shown in Table 45 is
in part related to the incidence of fracture (r=0.67, p=0.001)
and the healthcare spend per capita (r=0.63, p=0.004).
Denmark has the highest cost of osteoporosis per capita
with €190 per year, whereas Romania and Bulgaria had
the lowest cost per capita at approximately €6 per year.
4.3.2 Life-years lost due to fracture
As mentioned, hip, vertebral, and other fractures are associ-
ated with increased mortality and approximately 30 % of the
excess mortality may be attributable directly to the fracture
with each death resulting in approximately 2/3 life years
lost.
The total number of deaths after fracture in the EU27
in 2010 was estimated at about 143,000, with 43,000
(30 %) directly attributable to the fracture, resulting in
26,000 life years lost (i.e., 2/3 of the 43,000 attributable
deaths). The number of deaths after fracture, deaths
directly attributable to fracture, and resulting life years
lost are shown in Table 45.
4.3.3 QALYs lost due to osteoporosis
QALYs lost due to osteoporosis incorporate both the
HRQoL and life years lost due to fracture (downwards
adjusted to reflect the average health utility at the age in
which the death attributable to fracture occurred). The num-
ber of QALYs lost in 2010 was derived by applying the
health utility weights for incident and prior fractures to the
number of incident and prior fractures. Thereafter, the health
utility weighted life years lost were added.
Approximately 1,165,000 QALYs were lost due to oste-
oporosis in the EU27 in 2010. Women and men suffered
approximately 781,000 and 384,000 QALYs lost,
Fig. 27 Share (%) of 2010 cost of osteoporosis in EU27 (excluding
value of QALYs lost and cost of pharmacological intervention) by
fracture site
Table 43 Cost of osteoporosis (excluding value of QALYs lost and costs of pharmacological intervention) in EU27 by fracture site and age (€
million, 2010)
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respectively. Prior fractures were the main driver of QALYs
lost, accounting for approximately 58 % and 50 % of the
loss in women and men respectively. The higher proportion
of QALYs lost due to prior fractures in women than in men
reflects higher absolute mortality after fracture in men, a
pattern also observed in the number of prior fractures de-
scribed in Chapter 3. Germany was the individual country
where most QALYs were lost in both men and women,
followed by Italy for women and the UK for men. The
number of QALYs lost due to incident (including QALYs
lost due to deaths directly attributable to fracture) and prior
fractures for women and men in each of the EU27 countries
is shown in Table 46.
Hip fractures, vertebral, forearm and “other fractures” in-
curred approximately 600,000, 344,000, 19,000, and 202,000
QALYs lost, respectively. For hip and vertebral fractures,
approximately 79 % and 59 % of the QALYs lost were
incurred by prior fractures. Given that no long-term health
utility loss was assumed for forearm and other fracture, all
QALYs lost for these fracture types resulted from incident
fractures. The greatest number of QALYs lost in the EU27 in
2010 was incurred in people aged 80 to 90 years with 426,000
QALYS lost representing 37 % of the total. In this group, the
fracture type incurring highest number of QALYs lost was
prior hip fractures. The number of QALYs lost stratified by
age and fracture type is presented in Table 47.
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Table 44 Cost of osteoporosis in relation to population and healthcare spending (2010)
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Fig. 28 Estimated cost of osteporosis (excluding values of QALYs lost)
per capita (€, 2010)
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QALYs lost from fracture related deaths were included
in the estimate for incident fractures, reflecting that in-
creased mortality is accounted for within the first year
after fracture. These deaths amounted to approximately
26,000 life-years lost which corresponded to a loss of
about 13,000 QALYs, representing approximately 2.5 %
of the QALYs lost due to incident fractures and 1 % of all
QALYs lost.
Even though common, forearm fractures only represent-
ed a marginal share (1 %) of the estimated fracture-related
QALYs lost. The negligible impact of forearm fracture on
QALYs lost in the total population is due to its relatively
small impact on health utility during the first year after
fracture, no associated mortality and the complete long-
term recuperation after fracture assumed in the model. The
proportion of QALYs lost by incident and prior fracture are
shown in Fig. 29.
4.3.4 Value of QALYs lost due to osteoporosis
Valuing a QALY at 2 x GDP/capita resulted in a value of
QALYs lost due to osteoporotic fractures in 2010 of €60
billion. Country specific estimates of value of QALYs lost
ranged from €24 million in Malta to €15 billion in Ger-
many (Table 48).
Valuing a QALY at 2 x GDP/capita resulted in an
estimated cost of €121 for QALYs lost per capita in
the EU27 in 2010. Country specific estimates ranged
from €16 in Romania and Bulgaria to €307 in Denmark
(Fig. 30).
4.3.5 Cost of osteoporosis including value of QALYs
lost
When the cost of osteoporosis was combined with the value
for QALYs lost, valued at 2 x GDP, the cost of osteoporosis
amounted to €98 billion in the EU27 in 2010. The cost ranged
from €41 million in Malta to €24 billion in Germany.
QALYs lost accounted for 62 % of the total cost of osteo-
porosis including values of QALYs lost in the EU27 in 2010,
ranging from 50 % in Portugal to 87 % in Luxembourg.
Incident fractures, prior fractures and pharmacological inter-
vention accounted for 25%, 11% and 2%, respectively, of the
cost of osteoporosis including values of QALYs lost. The cost
136, Page 78 of 115
Table 45 Estimated number of deaths after fracture, deaths attributable to fracture, and life years lost due to attributable deaths in men and women
and (2010)
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of osteoporosis including the value of QALYs lost and the
proportion attributable to the different cost categories are
presented in Table 49.
4.3.6 Cost of osteoporosis compared to other diseases
The estimated cost of osteoporosis may be compared to the
cost of other diseases. However, given that the EU27 is a
relatively new construct, few directly comparable studies ex-
ist. Furthermore, methodological differences may render stud-
ies difficult to compare. However, a few studies conducted on
a similar geographic area with comparable methodology exist.
In a report issued by the European Brain Council, the
yearly societal costs for a number of brain disorders in the
EU27 were estimated at €105 billion for dementia, €43.5
billion for headache, €14.6 billion for multiple sclerosis, and
€13.9 billion for Parkinson’s disease [14, 111–113].
The cost of coronary heart disease and cerebrovascular
disease in the European Union (25 countries) has been
estimated at approximately €45 billion and €34 billion,
respectively, at 2003 prices [114]. For coronary heart dis-
ease, healthcare costs, productivity losses, and informal care
comprised 51 %, 34 % and 15 %, respectively. Costs for
pharmacological treatment accounted for 12 % of the total
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Table 46 Estimated number of QALYs lost due to fractures (2010)
Table 47 Number of QALYs lost due to fractures at different sites in respective age group in EU27 (2010)
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costs, substantially higher than for osteoporosis. For cere-
brovascular disease, healthcare costs, productivity losses,
and informal care comprised 61 %, 18 % and 21 % respec-
tively. Costs for pharmacological treatment accounted for
3 % of the total costs for cerebrovascular disease [114],
somewhat lower than for osteoporosis.
The cost of epilepsy in the European Union (25 coun-
tries) has been estimated at €15.5 billion at 2004 prices.
Healthcare costs comprised 18 % of costs, whereas direct
medical costs and productivity losses represented 27 % and
55 %, respectively [115].
Thus, in relation to other common non-communicable
diseases osteoporosis has major economic consequences
for society.
Osteoporosis shares some features of dementia, in that it
is a disease of the elderly population and is expected to take
an increasing share of healthcare spending when taking into
account the demographic changes expected with an ageing
population [116]. However, while large amounts of money
are being spent on research and development of new drugs
to treat dementia, there has been small or little success in
introducing new drugs to the market [117]. The availability
of affordable and efficient pharmacological treatment, as
well as non-pharmacological fracture risk prevention, pro-
vides an opportunity to take immediate action to reduce the
future number of osteoporotic fractures
4.4 Burden of osteoporosis up to 2025
Osteoporosis is a disease primarily affecting the elderly; the
prevalence of osteoporosis as judged by BMD criteria
Fig. 29 Proportion of QALYs lost by incident and prior fracture in the
EU27 2010
Table 48 Value of QALYs lost due to osteoporotic fractures (valued at 2×2010 GDP/capita per QALY; million €)
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Fig. 30 Value of QALYs lost (valued at 2×2010 GDP/capita per QALY) per capita (€)
Table 49 Total cost of osteoporosis including the value of QALYs lost (valued at 2×2010 GDP/capita per QALY) in million € and proportion of
costs attributable to different categories
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increases markedly with age. As described in Chapter 3, 6 %
of women aged 50–54 years have osteoporosis, and the
prevalence increases with age. Among women aged 80 years
or older 47 % have a BMD value in the osteoporosis range.
The determinants of the future burden of osteoporosis de-
pend on several factors in society, including changes in
population, age-specific fracture risk and measures to reduce
the risk of fracture. This section presents the projected bur-
den of osteoporosis in the European Union up to 2025 with
regard to the expected demographic changes.
4.4.1 Secular trends
Incidence rates can be followed over time using age-
standardized incidence rates. Age- and sex- specific risk of
fracture has been most completely studied in the case of hip
fractures. In general, age- and sex-adjusted hip fracture
incidence increased until the mid or end of the 20th century,
with a subsequent plateau or even decrease [118]. In Europe,
this tendency is best documented for Northern Europe. For
example, whilst Swedish crude hip fracture incidence has
increased, age-adjusted incidence (independent of demo-
graphic trends) remained stable between 1967 and 2001.
Palvanen et al. [119] also described this phenomenon for
humeral fractures and report a clear rise in the fracture rate
in Finnish women 60 years of age and older from 1970 until
the late 1990s followed by stabilisation and even decreased
fracture rates in later years. For the UK, hip fracture rates
have been reported to stabilise over the period 1989–1998
[120]. The trend has been further confirmed in Germany
[121], the Netherlands [122], Hungary [123] and Austria
[124]. There are fewer studies available from Southern
Europe. A Spanish study reported that the number of hip
fractures increased between 1988 and 2002, but no signifi-
cant change was observed in age-adjusted incidence rates
among men or women over this period [125].
The precise reasons for secular changes are unknown, and
both skeletal and non-skeletal mechanisms have been
suggested. An example of a non-skeletal factor is a cohort
effect towards improved functionality among older women
and actions and interventions in preventing and reducing falls.
The importance of functionality is exemplified by a recent
German study where 256 nursing homes were included in an
intervention programme aimed at reducing the risk of resi-
dents falling. This was done through measures such as
strength and balance training. Compared to control nursing
homes, the intervention led to a relative risk of femoral frac-
ture of 0.82 (95 % CI 0.72–0.93) [126]. An example of a risk
factor for skeletal health that changes over time is the effect on
maternal vitamin D status on offspring bone mass [127, 128].
The increasing use of drugs targeting osteoporosis could
also contribute to the decrease in incidence. However, since
incidence rates stabilized before treatment uptake rose
significantly [7], increased drug access is unlikely to be
the main reason for the secular trends observed.
For the purpose of this report we assume that incidence
rates have reached a plateau and will remain stable until
2025 consistent with the findings described above.
4.4.2 Demography up to 2025
The demographic projection in the European Union for the
years up to 2025 will translate into an increase in the number
of fractures, as age is an important risk factor for fractures and
the elderly population is projected to increase in almost all
countries. Estimates are based on the UN World Population
Projections using the medium variant [129]. In the European
Union, the population over 50 years is expected to increase
from 183million in 2010 to 219million in 2025, corresponding
to a rise of approximately 20 %, with the male to female ratio
increasing from 84 % to 87 %. When stratifying the population
by age groups, the highest growth is forecast for the population
aged 80 years or more (32% increase). Given a greater increase
in life expectancy in men than in women, the ratio of men to
women in the population over 80 years is forecast to increase
from 51 % to 60 % over the period. UN World Population
Projections for the EU-27 are shown in Table 50.
The estimated demographic changes differ for the individ-
ual countries (Figs. 31 and 32). In Bulgaria for example, the
male population above 50 years is expected to decrease by
1 %, whereas for all other countries the male population is
expected to increase in all age groups. In women aged 50–
74 years, the changes range from a 3% decrease in Bulgaria to
a 43 % increase in Luxembourg. In women aged 75 years and
above, the corresponding numbers are a 7% increase in Latvia
to a 63% increase in Cyprus. Spain andMalta are projected to
have the highest increase in men aged 50–74 years and 75+
years, respectively. The projections expressed in relative
change for countries with very small populations are uncertain
given that numbers are presented in 1000s by the UN.
Although the total population increases between 2010
and 2025, the population below 50 years is projected to
decrease by 7 % during the time period and the population
under 65 years is forecast to decrease by approximately 3 %
(Table 50). As a consequence, the projected increase in costs
of osteoporosis is forecast to be carried by a decreasing
population at productive ages.
4.4.3 Prevalence of osteoporosis as defined using the WHO
diagnostic criteria up to 2025
Assuming that the prevalence of osteoporosis (described in
Chapter 3), defined using theWHOdiagnostic criterion, remains
constant until 2025, the demographic changes are expected to
result in an increase in the number of individuals with osteopo-
rosis from 28 million in 2010 to 34 million in 2025,
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corresponding to an increase of 23 %. The increase is estimated
to be higher in men than in women (29 % vs. 22 %). In the
population aged 80 years and over, the overall increase is esti-
mated at 28 % with an even larger difference between men and
women (46 % vs. 25 %). The number of people with osteopo-
rosis stratified by five-year age groups is shown in Table 51.
4.4.4 Number of incident fractures up to 2025
Assuming that the incidence rates of fractures (see Chapter 3)
remain constant until 2025, the demographic changes are
expected to result in an increase in the number of incident
osteoporotic fractures from approximately 3.5 million in 2010
to approximately 4.5 million in 2025, corresponding to an
increase of 28 %. The absolute increase ranged from about
1,000 fractures in Malta to approximately 203,000 fractures in
Germany and the relative increase ranged from 4 % in Bul-
garia to 53% in Ireland. In 2025, Germany is expected to have
the largest number of fractures with approximately 928,000
fractures, followed by the UK with approximately 682,000
fractures. The estimated number of fractures in the EU27 in
2010 and 2025 is shown in Table 52.
Table 50 Population in thousands by age and sex [129]
Fig. 31 Relative change in demography in men by age group and
country between 2010 and 2025 (%)
Fig. 32 Relative change in demography in women by age group and
country between 2010 and 2025 (%)
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Table 51 Number of individuals with osteoporosis defined using the WHO diagnostic criteria
Table 52 Estimated number of fractures in 2010 and 2025
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Table 53 Number of fractures stratified by fracture type and sex in 2010 and 2025
Table 54 Cost of osteoporosis (excluding values of QALYs lost; million €) by country in 2010 and 2025
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The number of incident fractures in women and men is
expected to increase from approximately 2.3 million in 2010
to 2.9 million (25 %) in women and from 1.2 million to 1.6
million in men (34 %), respectively. Hip fractures are expected
to increase at the highest rate in both women (29 %) and men
(41 %). However, the increase in the number of fractures is
predominately driven by “other fractures”, accounting for
49 % of the increase in women and 61 % of the increase in
men. The number of fractures stratified by fracture type and
sex in 2010 and 2025 is shown in Table 53.
4.4.5 Cost of osteoporosis up to 2025 excluding QALYs lost
When costs of osteoporosis (excluding values of QALYs lost)
are estimated, three cost components are included in the
model: costs first year after fracture, costs subsequent years
Table 55 Cost of osteoporosis (excluding values of QALYs lost; million €) stratified by age and sex in 2010 and 2025
Table 56 Table QALYs lost by country in 2010 and 2025
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after fracture, and the cost of pharmacological intervention
including administration and monitoring costs. Fracture costs
are driven by the increased number of fractures. The ratio of
pharmacological intervention costs to fracture costs is as-
sumed to remain constant over the forecast period.
The cost of osteoporosis was projected to increase from €
37.4 billion in 2010 to € 46.8 billion in 2025, corresponding to
an increase of 25 % (Table 54). The absolute increase ranged
from €2million in Bulgaria to €2.3 billion in Germany and the
relative increase ranged from 5 % in Bulgaria to 47 % in
Cyprus.
The cost of osteoporosis excluding values of QALYs lost in
women and men was projected to increase from €25.8 billion
to €31.3 billion (21 %) and from €11.6 billion to €15.5 billion
Table 57 QALYs lost due to fracture stratified by age and incident and prior fracture in 2010 and 2025
Table 58 Total cost of osteoporosis including the value of QALYs lost (valued at 2*2010 GDP/capita per QALY; million €) in 2010 and 2025
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(34 %), respectively. The increase was projected to be most
pronounced in men aged 75 years and above (44 %). Whilst
the projected growth was most rapid in men, the majority of
the cost increase was incurred in women reflecting the sub-
stantially higher cost in women than in men in the index year
(2010). The cost of osteoporosis stratified by age and sex in
the EU27 in 2010 and 2025 is presented in Table 55.
4.4.6 Projection of QALYs lost due to osteoporosis
up to 2025
The increased number of fractures reflecting demographic
changes will affect the number of QALYs lost due to inci-
dent and prior fractures (Table 56). The number of QALYs
lost in the European Union was projected to increase from
1.17 million in 2010 to 1.40 million in 2025, corresponding
to an increase of approximately 20 %. The absolute increase
ranged from approximately 300 in Malta to approximately
50,000 in Germany and the relative increase ranged from
4 % in Bulgaria to 34 % in Ireland.
The number of QALYs lost due to fractures stratified by
age, sex and incident and prior fractures in 2010 and 2025 is
presented in Table 57. The number of QALYs lost (due to
incident and prior fractures jointly) was projected to increase
from approximately 781,000 to 911,000 (17%) in women and
from 384,000 to 491,000 (28 %) in men. The number of
QALYs lost (in both sexes jointly) was projected to increase
from approximately 520,000 to 669,000 (29 %) for the inci-
dent fractures and from 645,000 to 734,000 (14 %) for the
prior fractures.
4.4.7 Cost of osteoporosis up to 2025 including QALYs lost
When the costs of osteoporosis were combined with the
value for QALYs lost (valued at 2×GDP), the cost was
projected to increase from €98 billion in 2010 to €120
billion, corresponding to an increase of 23 % (Table 58).
The EU5 (Germany, France, Italy, Spain and the UK)
accounted for 74 % of the increase.
The cost of osteoporosis including QALYs lost in women
and men was projected to increase from €66 billion to €79
billion (19 %) and from €31 billion to €41 billion (31 %),
respectively. The increase was most pronounced in men aged
75 years and above (43 %). Whilst the projected growth was
most rapid in men, the majority of the projected increase was
incurred in women reflecting the substantially higher total cost
in women than in men in the index year (2010). The cost of
osteoporosis including values of QALYs lost stratified by age
and sex in 2010 and 2025 is shown in Table 59.
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5. Uptake of osteoporosis treatments
Summary
This chapter describes current and recent uptake of osteo-
porosis treatments in the European Union. Since data on the
number of patients treated are not readily available in most
European countries, international sales data (on volume in
mg and value (€)) on drugs used for treatment of osteopo-
rosis from IMS Health was used as a proxy. Sales data from
2001 to 2011 were analysed.
The drugs included in the analysis are alendronate,
denosumab, etidronate, ibandronate, parathyroid hormone
(PTH) 1–84, raloxifene, risedronate, strontium ranelate,
teriparatide and zoledronic acid. Four of these drugs re-
ceived marketing authorisation before 2001. The latest
drug to come to market was denosumab in 2010.
The results are presented as sales and defined daily dosages
(DDDs) per 100 of the total population. The number and
proportion of the population above 50 years that was treat-
ed was also estimated and expressed in relation to the
estimated number of patients considered eligible for
treatment.
The key messages of this chapter are:
Alendronate is the most commonly prescribed agent,
accounting for approximately a quarter of the total
value of sales. In terms of DDDs, alendronate represents
almost half of all DDDs used to treat osteoporosis in the
European Union.
The treatment uptake of osteoporosis drugs has increased
considerably during the study time, however, recently a
slight decrease has been observed.
The volume in terms of value of sales has decreased more than
the volume in terms of DDDs in the two most recent years,
mostly due to the decreasing price of generic bisphosphonates.
Uptake of individual treatments differs between regions in
Europe. In general, Southern Europe shows a higher uptake
of osteoporosis drugs.
There is a large gap between the number of women who are
treated compared to the proportion of the population that
could be considered eligible for treatment based on their
fracture risk.
5.1 Uptake of osteoporosis treatment
This section discusses the extent and type of osteopo-
rotic drugs used in the respective countries of the Eu-
ropean Union. In order to analyse the uptake of
treatments in different countries, data on the number
of patients currently treated, treatment type and treat-
ment compliance in each country are required. Unfortu-
nately, in most countries, individual patient data are not
readily available and there are only a few European
nations (e.g., the Nordic countries and the Netherlands)
that hold sufficiently large databases to allow a detailed
analysis on filled prescription at an individual level. In
the absence of country- and patient-specific data on
filled prescriptions, we utilised international sales data
in order to compare treatment uptake and osteoporosis
medication sales between countries and over time. A
similar, but more extensive, data analysis has been
performed for EU5 + Sweden report in a previous
report [1]. The analyses were conducted using interna-
tional sales of osteoporosis drugs from IMS Health to
estimate the use of osteoporosis treatment in the EU27
in value (€) and volume (DDD).
5.2 Data and methods
IMS Health data are currently the only source of com-
parative data on sales of pharmaceuticals at an interna-
tional level. However, the data have a number of
shortcomings. It is unlikely that 100 % of sales are
captured in any country, but it is difficult to define the
magnitude of underestimation. For some countries, it is
known that part or all of hospital sales are omitted and
that certain wholesalers or other channels of distribution
are not included. Similarly, it is possible that sales are
overestimated in some countries as a consequence of the
sample of pharmacies and hospitals that provide data.
Since IMS Health attempts to correct for under- and
over-estimation, and in the absence of any additional
information, we have refrained from any overall adjust-
ment of the available sales figures.
Another difficulty may arise from parallel trade. Al-
though drugs launched in the last two decades generally
have a rather narrow price band across Europe, price
control mechanisms, adaptation to distribution channels
and currency fluctuations have created a price difference
that give incentives for parallel trade. IMS Health ad-
justs the data for parallel trade but it is difficult to
estimate the accuracy of these corrections. Also, not
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all countries have adjustments for parallel trade. The
countries included in this report for which adjustments
have been made are: Austria, Belgium, Czech Republic,
Denmark, Finland, France, Germany, Italy, the Nether-
lands, Poland, Spain, Sweden and the UK.
The number of patients treated is an important com-
ponent in the analysis of treatment uptake. The IMS
Health sales data allow the estimation of how many
treatment years the sales volume can cover. However,
not all patients are completely adherent to therapy, and
such an approach would consequently result in an un-
derestimation of the actual number of patients that have
started a treatment since some patients only are treated
for a part of the year. This has further implications for
clinical outcome, and also means that the treatment
effect is lower than that reported from clinical trials
where persistence and compliance is high. To correct
for suboptimal adherence, an adjustment factor was
estimated from data from the Swedish Prescribed Drug
Register (see below). The adjustment factor was
employed irrespective of country because similar data
were not readily available for any other country. The
data from IMS Health were available as monthly num-
ber of defined daily doses (as defined by WHO, http://
www.whocc.no/atc_ddd_index [DDDs]) sold per coun-
try, and the following steps were included in the
estimations:
& For comparisons of uptake between countries, the
number of DDDs in each year was expressed as
DDDs/100 of the population aged 50 years or above
residing in the respective country [2]. This analysis
does not take into account that more women than
men are treated, potentially overestimating treatment
uptake in countries with a relatively high proportion
of women over 50 years of age and vice versa.
However, the proportion of women and men eligible
for treatment that could be treated is assessed in a
separate analysis.
& Almost all osteoporosis drugs are prescribed to patients
aged 50 years or older (97.2 % based on Swedish pre-
scription data). Therefore, it was assumed that only
patients 50 years or older were given osteoporosis
treatments.
& Population coverage is the proportion of the population
at or above the age of 50 years in each country that could
theoretically be covered by a full year of treatment based
on the sales volume. It can be estimated by dividing the
DDDs per 100 of the total population by 365 (alterna-
tively 366 days in a leap year).
& Based on an analysis of filled prescriptions from the
Swedish Prescribed Drug Register between 2006
and 2009, it was estimated that the total volume
of the prescription could cover 73 % of the total
observed time (i.e., the sum of the days from treat-
ment start to end of the year) for all patients that
were prescribed an osteoporosis treatment during
this period. This estimate was not found to vary
with age. This factor was used to approximate the
number of patients being treated during a year for
all countries.
& Additionally, to differentiate between men and women,
it was assumed that 87 % of the sales were directed to
women and 13 % to men. This assumption was made
based on Swedish prescription data.
No data were available for Cyprus or Malta and these two
countries were therefore excluded from all analyses of treat-
ment uptake and population coverage.
5.3 Pharmacological treatment
There are a number of pharmacological options avail-
able in the European Union for the treatment of osteo-
porosis. Table 60 shows the year of introduction in
Europe (EMA marketing authorisation) for the agents
indicated for osteoporosis. The bisphosphonates were
the first group of drugs to be approved, followed by
the SERM raloxifene in 1998. In the 2000s, additional
bisphosphonates as well as novel groups of drugs have
become available. The patent of alendronate expired and
generic versions of the drug became available in Europe
in 2006. Also risedronate has been available in generic
formulations since 2010.
Table 60 Year of first introduction in Europe
Page 93 of 115, 136Arch Osteoporos (2013) 8:136
The introduction of generic versions has, as expected,
driven prices downwards, albeit by a different extent in dif-
ferent countries. The annual prices of generic alendronate and
other medications indicated for osteoporosis are shown in
Table 61. The prices differ markedly between the countries,
e.g., the yearly price of generic alendronate ranges from €4 in
the Netherlands to €327 in Cyprus, and generic risedronate
from €19 in Belgium to €514 in Ireland.
5.4 Market shares
Data on estimated population-adjusted total sales and
market shares, presented as sales of DDDs and in
Euros, are shown in Figs. 33 and 34 for the time period
2001 through 2011 (and related to the size of the
population). In terms of value, sales increased rapidly
from 2001 to 2005; grew at a slower pace until 2008
and thereafter decreased. Over the entire period, the
value of sales in the EU27 increased from approximate-
ly €344/100 persons aged 50 or above in 2001 to €883
in 2011. In terms of volume (DDDs per 100 person-
years aged 50 or above) sales increased almost linearly
until 2010 decreased slightly in 2011. The discrepancy
between the development of sales in terms of value and
volume was predominately driven by the decreased
price of generic alendronate. DDDs per 100 person-
years and value of sales for each drug and country are
presented in the compendium of country specific sum-
maries published concurrently with this report.
Estimated sales per product in 2010 measured both as
DDDs and in Euros along with market shares are shown in
Table 62. A comparison of market shares measured as sales
and volume shows a substantially higher market share in terms
of volume than in sales for alendronate, reflecting the low
price of generic alendronate. Conversely, the effect of high
price is seen with PTH and teriparatide, which have higher
market shares in sales than in volume.
Table 61 Yearly cost (€) of treatment with respective medications indicated for osteoporosis treatment
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Fig. 33 Estimated market shares in EU27 2001–2011 (sales in
Euros/100 persons aged 50 years or above)
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The estimated value of sales per region of the European
Union (Northern, Western, Eastern and Southern Europe) for
osteoporotic drugs is shown in Figs. 35 to 38. In Northern
and Eastern Europe, sales per 100 persons aged 50 years or
above were generally lower than the average for EU27,
whilst the opposite was observed for countries from Western
and Southern Europe.
The average cost perDDDby region is presented in Figs. 39
to 42. Across all regions, the average cost per DDD remained
stable from 2001 to 2005 and subsequently decreased year on
year until 2011. If inflation during these years is taken into
account, the decrease would be even more marked.
The largest and smallest intra-region variation was
observed in Eastern and Southern Europe, respectively.
In Western Europe, cost per DDD was comparatively
homogenous in 2001 but variation increased thereafter.
A similar pattern, albeit less marked, was observed in
Northern Europe. Much of the variation seen in the cost
per DDD can be explained by the market penetration of
generic alendronate. The most notable decrease in cost
per DDD was observed in the UK (€1.64 in 2001 to
€0.24 in 2011).
5.5 Population coverage
The population coverage estimations are calculated, as de-
scribed in the Data and Methods section, using the DDDs
sold per year adjusted by the proportion of the population
over 50 years that could be treated. This estimate is subse-
quently adjusted for suboptimal compliance. For the Euro-
pean Union in total, there seems to be an increase up until
2008, followed by a subsequent plateau or even a decrease
in population coverage. The uptake differs among the re-
gions of the European Union, as is shown in Figs. 43 to 46.
Generally, uptake is lower than the average for EU27 in
Northern and Eastern Europe (exceptions being Ireland and
to some extent Hungary), whilst Western Europe shows
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Fig. 34 Estimated market shares in EU27 2001–2011 (DDDs/100
persons aged 50 years or above)
Table 62 Estimated sales in EU27 and market shares in 2010 based on IMS Health data
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Fig. 35 Estimated annual sales in Northern Europe 2001–2011 (€/100
persons aged 50 years or above)
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Fig. 36 Estimated annual sales in Western Europe 2001–2011 (€/100
persons aged 50 years or above)
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Fig. 37 Estimated annual sales in Eastern Europe 2001–2011 (€/100
persons aged 50 years or above)
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Fig. 38 Estimated annual sales in Southern Europe 2001–2011 (€/100
persons aged 50 years or above)
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Fig. 39 Cost (€) per DDD in Northern Europe: average for all drugs
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Fig. 40 Cost (€) per DDD in Western Europe: average for all drugs
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Fig. 41 Cost (€) per DDD in Eastern Europe: average for all drugs
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slightly higher population coverage. There is no country in
Southern Europe that has a lower coverage than the EU27
average from 2010. In 2010, the proportion of persons, aged
50 years or more, potentially treated (assuming treatment for
73 % of the year) ranged from approximately 0.5 % in
Bulgaria to 9.3 % in Spain.
5.6 Uptake of individual treatments
The uptake, measured by DDDs per 100 of the population
aged 50 years or more stratified by country, is shown in the
figures below. The countries are grouped into four regions
as discussed above.
5.6.1 Alendronate
The general trend in the EU27 of the uptake of alendronate
was an increase from 2001 to approximately 2008, followed
by a plateau. A slight decrease was noted in 2011. This is in
sharp contrast to statins, for example simvastatin, where
after patent expiration the sales in volume more than dou-
bled. In the UK, treatments for hypercholesterolaemia and
osteoporosis have been available for a similar time period;
simvastatin was introduced in 1989 and etidronate in 1992.
Simvastatin and alendronate were the most prescribed prod-
ucts in their drug class prior to the introduction of cheap
generic equivalents in 2003 and 2005, respectively. In 2007
there was, however, a 5-fold difference between peak annual
drug spend on statins and osteoporosis drugs indicating
significantly different levels of clinical activity in these
two chronic diseases [24]. There may be several reasons
for the observed development. One is that there are fewer
incentives to market the product or that better alternatives
are available. This seems unlikely given the continued dom-
inance of alendronate in the market and the contraction of
the general market. A possible factor may be that persistence
has reduced over time, and there is some evidence that
generic formulations are associated with a greater frequency
of adverse effects and poorer persistence than proprietary
formulations [25]. The factor that is likely to have affected
the market, particularly the bisphosphonates, is the wide
publicity given to rare side effects so that many doctors
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Fig. 42 Cost (€) per DDD in Southern Europe: average for all drugs
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Fig. 43 Estimated proportion (%) of the population 50 years or older
treated in Northern Europe
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treated in Western Europe
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Fig. 45 Estimated proportion (%) of the population 50 years or older
treated in Eastern Europe
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and patients are more frightened of the side effects than they
are of the disease.
The three countries with the highest uptake of
alendronate in 2010 were Hungary, Ireland and the UK with
approximately 1.68, 1.17 and 1.14 million DDDs per 100
persons aged 50 years or above, respectively. The three
countries with the lowest uptake in 2010 were Bulgaria,
Lithuania and Slovakia (42, 74 and 75 DDDs per 100
persons aged 50 years or above, respectively). The differ-
ence between the country with the highest and the lowest
uptake was thus 40-fold. However, it should be noted that
sales from Hungary, for example, are not adjusted for par-
allel trade, which consequently could be a reason for the
high numbers estimated for this country.
In Northern Europe, Baltic countries were below the
average for the EU27 (Fig. 47) whereas Denmark, Ireland
and the UK were above the average. Finland showed a
three-fold increase in uptake between 2001 and 2006,
followed by a decrease over the next 5 years, resulting in a
below average uptake in 2011. The highest increase in
uptake was observed in Denmark.
In Western Europe, except for Germany, most countries
showed an above average uptake for most of the period
(Fig. 48). Uptake in all countries decreased in recent
years, so that in 2010, Germany, France and Luxemburg
had a below average uptake in 2011.
In Eastern Europe, all countries except Hungary had
lower uptake than the EU27 average (Fig. 49). The
converse was noted for Southern Europe where all
countries showed higher uptake than the EU27 average
(Fig. 50). Slovenia and Portugal showed a marked de-
crease in the last few years.
5.6.2 Denosumab
The latest drug to be introduced for treatment of osteoporo-
sis was denosumab—a monoclonal antibody. It was
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Fig. 47 Uptake of alendronate in Northern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 46 Estimated proportion (%) of the population 50 years or older
treated in Southern Europe
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Fig. 48 Uptake of alendronate in Western Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 49 Uptake of alendronate in Eastern Europe (DDDs per 100
persons aged 50 years or above)
136, Page 98 of 115 Arch Osteoporos (2013) 8:136
introduced in 2010, and approved in nine EU countries the
same year. In 2011, denosumab was sold in all countries
except France, Greece and Portugal. The highest uptake in
2010 was observed in Denmark and Germany with uptakes
of 8.4 and 6.4 DDD per 100 persons aged 50 years or above,
respectively, and in 2011 in Slovakia (160 DDDs per 100
persons aged 50 years or above) (Fig. 51).
5.6.3 Etidronate
In 2011, etidronate was marketed in 11 EU countries. Over-
all, the uptake decreased markedly from 76 DDDs in 2001
per 100 persons aged 50 years or above to 3 DDDs per 100
persons aged 50 years or above in 2011. The phenomenon
likely reflects the availability of new bisphosphonates with
more robust evidence for efficacy. Sweden had the highest
uptake of the countries in Northern Europe, whilst there was
no uptake in Lithuania (Fig. 52). Of the countries in Western
Europe, France followed the aggregated estimates for EU27,
while there was higher uptake in Germany and the Nether-
lands and lower uptake than average in the other countries
(Fig. 53). In Eastern Europe, etidronate was not marketed
after 2005 (Fig. 54). Also in Southern Europe the uptake
was low (Fig. 55). This decrease in uptake for etidronate
may reflect the superior evidence that alendronate and other
pharmacological therapies reduce fracture rates more than
etidronate.
5.6.4 Ibandronate
Since the first approval of ibandronate for treatment
of osteoporosis in 2005, the uptake increased in all
countries (except for Sweden where ibandronate is not
available for the treatment of osteoporosis) (Figs. 56–
59). The highest uptake in 2010 was seen in Spain,
Greece and Slovenia (438, 426, and 407 DDDs per
DDDs /100 person-years
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Fig. 50 Uptake of alendronate in Southern Europe (DDDs/100 persons
aged 50 years or above)
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Fig. 51 Uptake of denosumab in 2010 (DDDs per 100 persons aged
50 years or above)
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Fig. 52 Uptake of etidronate in Northern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 53 Uptake of etidronate in Western Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 54 Uptake of etidronate in Eastern Europe (DDDs per 100 persons
aged 50 years or above)
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Fig. 55 Uptake of etidronate in Southern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 56 Uptake of ibandronate in Northern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 57 Uptake of ibandronate in Western Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 58 Uptake of ibandronate in Eastern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 59 Uptake of ibandronate in Southern Europe (DDDs per 100
persons aged 50 years or above)
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100 persons aged 50 years or above, respectively).
Apart from Sweden, Austria (2.2 DDDs per 100 per-
sons aged 50 years or above), Hungary (15.1 DDDs
per 100 persons aged 50 years or above) and Germa-
ny (30.6 DDDs per 100 persons aged 50 years or
above) show the lowest uptake in 2010. When esti-
mating the uptake of ibandronate, only prescriptions
for osteoporosis and not cancer related treatment were
considered.
5.6.5 PTH (1–84)
The first sales of PTH were registered in 2006. PTH
(1–84) is the recombinant full-length PTH protein (ami-
no acids 1–84), in contrast to teriparatide, which com-
prises the first 34 amino acids of PTH. In 2011, PTH
was sold in 16 out of 27 countries in the European
Union. In 2010, the highest uptake was observed in
Greece, followed by Denmark and Slovakia (11.2, 4.8.
and 4.4 DDDs/100 persons aged 50 years or above,
respectively) (Figs. 60–63).
5.6.6 Raloxifene
In the European Union, the uptake of raloxifene in-
creased from 2001 to 2005 and then decreased contin-
uously. Raloxifene has been shown to increase the risk
of venous thromboembolic events when compared to
controls. On the other hand, beneficial effects on the
risk of breast cancer were seen [26]. The uptake of
raloxifene was highest in Spain throughout the time
period studied, followed by France and Portugal (232,
202, and 167 DDDs per 100 persons aged 50 years or
above, respectively, in 2010). Latvia and Estonia had
virtually no uptake of this drug. By region, the uptake
was highest in Southern Europe and lowest in Northern
and Eastern Europe (Figs. 64 to 67).
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Fig. 60 Uptake of PTH in Northern Europe (DDDs per 100 persons
aged 50 years or above)
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Fig. 61 Uptake of PTH in Western Europe (DDDs per 100 persons
aged 50 years or above)
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Fig. 62 Uptake of PTH in Eastern Europe (DDDs per 100 persons aged
50 years or above)
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Fig. 63 Uptake of PTH in Southern Europe (DDDs per 100 persons
aged 50 years or above)
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5.6.7 Risedronate
The uptake of risedronate increased rapidly between
2001 and 2006 but has not changed substantially be-
tween 2006 and 2010 when studied at the level of the
European Union, although a slight downward trend is
evident in later years (Figs. 68–71). In individual coun-
tries, uptake is seen both to increase (e.g., in Slovakia,
Spain and Greece) and decrease substantially (e.g., in
Austria, Germany and Portugal) over the last 5 years.
The highest uptake in 2010 was seen in Spain (715
DDDs per 100 persons aged 50 years or above), Slova-
kia (606 DDDs per 100 persons aged 50 years or
above) and Greece (603 DDDs per 100 persons aged
50 years or above) whilst the lowest was seen in Poland
(9.7 DDDs per 100 persons aged 50 years or above),
Bulgaria (18.9 DDDs per 100 persons aged 50 years or
above) and Denmark (21 DDDs per 100 persons aged
50 years or above).
5.6.8 Strontium ranelate
Strontium ranelate showed a progressive increase in
uptake in the European Union since its introduction
on the market in 2004. This was also the case for most
individual countries (exceptions being Latvia, Lithuania
and Poland). The uptake by region is shown in Figs. 72
to 75. Although there was a continuous increase, most
countries showed modest absolute uptake of strontium
ranelate. Portugal had the highest increase and level of
uptake (263 DDDs per 100 persons aged 50 or above
in 2010). In Northern, Eastern and Western Europe, all
countries but three had an uptake below the average
European uptake. In Southern Europe on the other
hand, all countries had an uptake above the European
average.
5.6.9 Teriparatide
Teriparatide is the more commonly used of the two PTH
peptides available for treatment of osteoporosis (i.e.,
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Fig. 64 Uptake of raloxifene in Northern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 65 Uptake of raloxifene in Western Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 67 Uptake of raloxifene in Southern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 66 Uptake of raloxifene in Eastern Europe (DDDs per 100 persons
aged 50 years or above)
136, Page 102 of 115 Arch Osteoporos (2013) 8:136
0
100
200
300
400
500
600
700
800
Year
Denmark
Estonia
Finland
Ireland
Latvia
Lithuania
Sweden
UK
EU27
DDDs /100 person-years
Fig. 68 Uptake of risedronate (DDDs per 100 persons aged 50 years or
above) in Northern Europe
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Fig. 69 Uptake of risedronate (DDDs per 100 persons aged 50 years or
above) in Western Europe
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Fig. 70 Uptake of risedronate (DDDs (per 100 persons aged 50 years or
above) in Eastern Europe
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Fig. 71 Uptake of risedronate (DDDs (per 100 persons aged 50 years or
above) in Southern Europe
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Fig. 72 Uptake of strontium ranelate in Northern Europe (DDDs per
100 persons aged 50 years or above)
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Fig. 73 Uptake of strontium ranelate in Western Europe (DDDs per
100 persons aged 50 years or above)
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Fig. 74 Uptake of strontium ranelate in Eastern Europe (DDDs (per
100 persons aged 50 years or above)
0
50
100
150
200
250
300
Year
Greece
Italy
Portugal
Slovenia
Spain
EU27
DDDs /100 person-years 
Fig. 75 Uptake of strontium ranelate in Southern Europe (DDDs per
100 persons aged 50 years or above)
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Fig. 76 Uptake of teriparatide in Northern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 77 Uptake of teriparatide in Western Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 78 Uptake of teriparatide in Eastern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 79 Uptake of teriparatide in Southern Europe (DDDs per 100
persons aged 50 years or above)
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teriparatide and PTH). It is sold in all countries of the
European Union except in Bulgaria. Even though there has
been a steady increase in uptake of teriparatide since its
introduction on the market in 2003, the absolute numbers
remain low. Up until 2011, sales were highest in Greece
(peaking at 54 DDDs per 100 persons aged 50 or above in
2009). In 2011, sales were highest in Spain, estimated at 41
DDDs per 100, persons aged 50 years or above, in 2010.
The uptake per region is shown in Figs. 76 to 79. Compared
to other regions, Eastern Europe had a low uptake of
teriparatide.
5.6.10 Zoledronic acid
The uptake of zoledronic acid increased steeply since its
approval for osteoporosis in 2005. Note that cancer-related
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Fig. 80 Uptake of zoledronic acid in Northern Europe (DDDs per 100
persons aged 50 years or above)
Luxembourg
Netherlands
0
50
100
150
200
250
Year
Austria
Belgium
France
Germany
EU27
DDDs /100 person-years 
Fig. 81 Uptake of zoledronic acid in Western Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 82 Uptake of zoledronic acid in Eastern Europe (DDDs per 100
persons aged 50 years or above)
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Fig. 83 Uptake of zoledronic acid in Southern Europe (DDDs per 100
persons aged 50 years or above)
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use of zoledronic acid was not included in this analysis.
Figures 80 to 83 show uptake of zoledronic acid in North-
ern, Western, Eastern and Southern Europe, respectively.
The pattern of uptake was different with zoledronic acid
compared to most other drugs, with highest uptake in
Western and Eastern Europe and lowest in Northern and
Southern Europe. The individual country with the highest
uptake was Belgium, followed by Slovakia (196 and 156
DDDs per 100 persons aged 50 years or above in 2010,
respectively). Luxembourg and Estonia had very low up-
takes of zoledronic acid.
5.6.11 Summary
Overall, these data indicate a decrease in the population
coverage in the last 2 years (i.e., the proportion of the
population treated at or above the age of 50 years).
Also the pattern of drugs prescribed has changed over
the 11 years studied (2001–2011). The population cov-
erage varies substantially between countries. Ireland is
the country where the highest proportion of the popu-
lation over 50 years is treated, followed by Spain and
Greece. The high numbers observed for Ireland and
Greece could be a result of parallel trade, since the
data from IMS Health were not corrected for this factor
in these countries. The lowest proportions treated were
found in Bulgaria, Romania and the Baltic States. In
Bulgaria, 0.5 % of the population above 50 years is
treated. This can be compared to population coverage
of almost 9 % in Ireland. The uptake of etidronate and
raloxifene was observed to decrease over the study
period, whereas the uptake of all other treatments was
generally observed to increase. As expected, the in-
crease was highest for drugs approved within the study
period. In all years of analysis, the drug with the
highest uptake was alendronate. As mentioned in the
Data and methods section however, all analyses should
be interpreted with caution since the original sales data
are imperfect.
The most disturbing finding is the plateau and down-
ward trend in the number of patients being treated. The
Table 63 FRAX 10-year probability (%) of a major osteoporotic fracture in women with a previous fracture (no other clinical risk factors, BMI of
24 kg/m2 and without BMD)
*surrogate country used
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phenomenon is most marked in the case of the
bisphosphonates (Fig. 84). As noted above, many doc-
tors and patients are more frightened of the rare but
serious side effects than they are of the disease. The substan-
tial difference in prescribing for hypercholesterolaemia and
osteoporosis may also arise because of inconsistent ap-
proaches to health technology assessment. For example,
the 2008 NICE Technology Appraisals [27, 28] on
osteoporosis treatments in the UK restricted access to
more costly second-line agents other than generic
alendronate until BMD was lower, the patient older or
they developed more clinical risk factors. This was not
the case for second-line statin therapies described in the
relevant guidance (NICE TA 94). This inconsistency of
recommendations in the two disease areas is surprising
given the volume and costs incurred by the prescribing
of non-generic statins by the NHS in England compared
to that for bone remodelling agents.
5.7 Patients eligible for treatments and treatment gap
To estimate the proportion of patients treated out of those
eligible for treatment, it is necessary to define an interven-
tion threshold. There are several approaches to estimate
intervention thresholds; they have traditionally been esti-
mated on the basis of T-score for BMD with little consid-
eration of cost-effectiveness. This approach is still largely
reflected in the guidance in several European countries.
Efforts have also been made to develop intervention
thresholds in osteoporosis treatment based on cost-
effectiveness. In Europe, several studies have described the
hip fracture probability at or over which treatment becomes
cost-effective [29–32].
The advent of FRAX (www.shef.ac.uk/FRAX) in 2008
provided a clinical tool for the calculation of fracture prob-
ability which can be applied to the development of
intervention thresholds [33]. Application of FRAX in
Table 64 The proportion (%) of the male population in each age category at or above a probability based fracture threshold
*surrogate country used
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clinical practice provides a tool for determination of the
fracture probability at which to intervene. This can be
done using two approaches: firstly to translate the cur-
rent practice in the light of FRAX and justify the
thresholds developed by cost-effectiveness analyses or
secondly, to determine the fracture probability at which
intervention becomes cost-effective. The second ap-
proach has been used in North America [34, 35] where-
as the former has been favoured in Europe.
The UK guidance for the identification of individuals
at high fracture risk developed by the NOGG is an
example of the translation of former guidance provided
by the Royal College of Physicians (RCP) [36, 37] into
probability based assessment [37]. The RCP guidance
indicates that women with a prior fragility fracture may
be considered for intervention without the necessity for a
BMD test, and the management of women over the age
of 50 years on this basis has been shown to be cost-
effective [38]. For this reason, the intervention threshold
set by NOGG was at the 10-year fracture probability
equivalent to women with a prior fragility fracture
without knowledge of BMD [36]. Thus, the intervention
threshold can be likened to a fracture threshold expressed
in terms of fracture probability. The same intervention
threshold was applied to men, since the effectiveness of
intervention in men is broadly similar to that in women
for equivalent risk. This translational approach from
existing treatment guidelines is characterised by an inter-
vention threshold that increases progressively with age.
The major reason for this is that the source guidelines
took little or no account of age. Since age is an impor-
tant independent factor for fracture risk, the fracture
probability of an individual with a prior fracture is higher
at the age of 70 years than at the age of 50 years. This
age-dependent increase in the intervention threshold is
not found when intervention thresholds are derived from
health economic analyses alone [37].
The NOGG guideline provides an opportunity to
determine the burden of disease in terms of FRAX.
In other words, to determine the number of individ-
uals that have a 10-year fracture probability that is
equivalent to or exceeds the fracture threshold (i.e.,
Table 65 The proportion (%) of the female population in each age category at or above a probability based fracture threshold
*surrogate country used
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the age and country specific probability of fracture in
a woman with a prior fragility fracture). The 10-year
probability of a major osteoporotic fracture of women
at the fracture threshold is provided for the countries
of the European Union for different ages in Table 63.
The fracture thresholds differ between countries due
to the differences in fracture risk in the respective
countries. For example, the fracture threshold at the
age of 87 years ranged from a 10-year probability of
12 % (Bulgaria and Romania) to 46 % (Denmark).
Note that FRAX models are not available for Bulgar-
ia, Cyprus, Estonia, Latvia, Luxembourg and Slove-
nia. For these countries surrogate FRAX models were
used (Romania, Malta, Lithuania, Lithuania, Belgium
and Hungary, respectively). The surrogate countries
were chosen on the likelihood that the fracture rate
(and mortality) was similar to that of the index
country.
The proportion of men and women who exceed the
probability threshold for fracture can be computed by
simulation based on the distribution of the risk-score
among the cohorts used by WHO to develop FRAX
and the epidemiology of fracture and death in each EU
country. Tables 64 and 65 show the proportion of men
and women with a probability of a major osteoporotic
fracture exceeding that of a woman with a previous
fracture and no other clinical risk factor, an average
BMI and unknown BMD. This proportion, which in
this report represents the proportion that could be eli-
gible for treatment, varied between countries and by
age and sex. The relative difference between countries
was larger in men than in women. Greece and the UK
appear to have the highest proportion of women falling
above the fracture threshold, whilst the UK shows the
lowest proportion of men. This variation across coun-
tries is caused by differences in fracture risk between
women and men and differences in population preva-
lence of the risk factors used by FRAX.
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Combined with UN data on population demography [39],
the resulting number of persons with a fracture probability at
or above the fracture threshold, and thus here regarded
eligible for treatment, is shown for the countries of the
European Union in Figs. 85 and 86.
5.8 Proportion of patients treated
Figures 87 and 88 show the number of men and women
that could be treated for the year 2010 given sales in
2010 and adjusted for suboptimal adherence, compared
to the remaining number of persons eligible for treat-
ment according to risks described in the section above.
The proportion of patients estimated to be eligible for
treatment but not receiving treatment can be viewed as
an approximation of the treatment gap. The treatment
gap varies between countries, in accordance with differ-
ent sales of anti-osteoporotic treatments as well as dif-
ferences in fracture risk between countries. The highest
treatment gap for women is noted for Bulgaria and the
Baltic states, where less than 15 % of the population
eligible for treatment receives an osteoporotic drug. The
same countries, with the addition of Romania, also
show the highest treatment gap for men.
All of the countries in the European Union have higher
estimates for women that should be treated than the esti-
mates of patients actually treated. The lowest treatment gap
is seen for Spain, where sales are high and fracture risks
relatively low, with approximately 75 % of the women
eligible for treatment potentially treated. Other countries
with low treatment gaps are Ireland and Hungary. More
detailed data for men and women are shown in Table 66
and Table 67, respectively.
For men, the data indicate that the volume of sold oste-
oporosis drugs would be sufficient to cover treatment for
more patients than the number that fall above the fracture
threshold in Greece, Luxembourg and the UK. It should be
noted, however, that the results from this analysis should be
interpreted with some caution since it has been assumed that
the distribution of drug use between genders observed in
Sweden is valid for all countries. In addition, it is not known
how well treatment is targeted to the high risk population. In
total in the EU, 1.7 million men out of the 2.9 million men
that exceed the risk level are not treated. Corresponding
numbers for women are 10.6 million out of 18.4 million
women exceeding the fracture threshold.
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Fig. 87 Estimated number (in thousands) of men treated (blue) and
patients eligible for treatment that are not treated (red) in 2010
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These analyses suggest that there is wide inter-
country variation in the treatment penetration of women
with higher risk for osteoporotic fractures. Large treat-
ment gaps are identified in countries with populations of
both high and low risks of fracture. The strength of the
information based on IMS Health data is that informa-
tion is available for nearly all EU member states. How-
ever, the pattern of use cannot be ascertained, so that it
is not possible to determine whether treatment is
targeted appropriately to high risk individuals. There
are several indicators that suggest that the targeting of
treatment is heterogeneous in the EU. Good evidence
comes from the Global Longitudinal Study of Osteopo-
rosis in Women (GLOW) which is a general practice
based observational cohort study in women aged 55 years
or more conducted in 10 countries, including several EU
countries [40]. In the EU, there was heterogeneity of
treatment uptake between countries with the lowest pro-
portion of women aged 55 years or more treated in the
Netherlands (7 %) and the highest in Spain (23 %) (Fig.
89). Although treatment uptake was higher in women at
very high risk (a prior hip or spine fracture), a minority
(45 %) was receiving treatment in these countries.
Again, there was heterogeneity in treatment uptake with
a range from 36 % in the Netherlands to 57 % in Italy.
Moreover, some low risk women were targeted in all
countries.
These data demonstrate that a large number of women at
high risk of fractures are not receiving treatment, that a
substantial number of women at low risk are prescribed
treatment and that there are important differences in the
uptake of treatment between countries.
The differences could not be explained by other clinical
risk factors, and the regional difference in probability of
treatment thus seems to have little correlation to existing
evidence of best practice and cost-effectiveness.
Comparing data for Sweden from IMS Health and the
Swedish Drug Register and Sales Data
To validate the data from IMS Health, a comparison of
the data was made with data from the Swedish Pre-
scribed Drug Register. Information on all filled prescrip-
tions outside of the hospital setting are available from
2006 (available on the website of National Board of
Health and Welfare [www.sos.se]). The database
Table 66 Number of men eligible for treatment, treated and treatment gap in 2010
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contains information on the number of patients filling a
prescription, the number of prescriptions and the num-
ber of DDDs. Figure 90 shows the number of DDDs of
alendronate sold as reported by the Swedish drug reg-
istry database and by IMS Health. These numbers cor-
respond well with the data in this report, although IMS
Health reports slightly higher numbers (2–3 %).
Table 67 Number of women eligible for treatment, treated and treatment gap in 2010
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Proportion treated (%)
Fig. 89 Proportion of women, included in the GLOW study, receiving
treatment in six EU member states according to category of risk. All
women refer to women aged 55 years or more (n=24,249). Low risk
comprises women aged less than 75 years with a T-score for BMD in
the range of osteopenia, no prior fracture, no maternal hip fracture or
osteoporosis (n=1166). High risk refers to women reported to have a
BMD measurement in the range of osteoporosis (n=5258). Very high
risk comprises women with a previous hip or spine fracture (n=913)
[41]
Fig. 90 DDDs of alendronate sold in Sweden as reported by IMS
Health and the Swedish Prescribed Drug Register
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Comparison of bisphosphonates used in cancer treatment
is not as easily undertaken since only data from IMS
Health discriminates the two indications.
The sales of teriparatide, on the other hand, show a
greater discrepancy between the numbers from the Swedish
Prescribed Drug Register and IMS Health, and the trend is
reversed with IMS Health data being 14–17 % lower than
the numbers from the Swedish Prescribed Drug Register
(Fig. 91). The reasons for these differences, however small,
are not evident, since neither the data from IMS Health nor
the Swedish registry data claim to take hospital use into
account.
Using Swedish data from the National Board of Health
and Welfare, it appears that treatment variation could exist
within countries as well as between countries, suggesting a
lack of evidence based treatment for osteoporosis on the
national level: Among the 21 county councils in Sweden,
the number of women aged over 50 years per 1,000 who
filled at least on prescription of medications used to treat
osteoporosis (ATC code M05B) in 2011 ranged from 36 to
63 (Fig. 92) with an average of 48.
This variation in prescription rates among counties does
not appear to be explained by differences in fracture risk
given that there were no significant correlations (r=−0.3 p=
0.9) between prescription and hip fracture rates (ICD-10
code S72) (Fig. 93).
Fig. 91 DDDs of teriparatide sold in Sweden as reported by IMS
Health and the Swedish Prescribed Drug Register
Fig. 92 Number of women per (1,000) aged 50 years or above prescribed medication to treat osteoporosis (M05B)
Fig. 93 Correlation of hip fracture and prescription rates on county
level in women aged 50 years or above in Sweden 2011
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